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ABSTRACT 
 
 
Pyruvate dehydrogenase kinase 4 (PDK4) regulates pyruvate oxidation through 
the phosphorylation and inhibition of the pyruvate dehydrogenase complex (PDC). The 
PDC catalyzes the conversion of pyruvate to acetyl-CoA and it is an important control 
point in glucose and pyruvate metabolism. Previous studies had reported that PDK4 gene 
expression is induced by thyroid hormone (T3). These studies did not investigate the 
mechanisms by which T3 regulated PDK4 gene expression.  I have examined the role of 
the thyroid hormone receptor (TR), transcriptional coactivators especially the peroxisome 
proliferator activated receptor gamma coactivator-1 (PGC-1α) and other transcription 
factors that act as accessory factors in T3 actions.  
 
Thyroid hormone receptors (TRα or TRβ) are part of the nuclear receptor family 
and have been implicated in the induction of many genes by T3. The nuclear receptors 
constitute a broad class of transcription factors that have the ability to bind to DNA and 
regulate the expression of the genes in a ligand dependent manner. To identify a binding 
site for the TRβ in the promoter of the PDK4 gene, I transfected serial deletions of this 
promoter ligated to the luciferase reporter gene into the human hepatoma (HepG2) cells. 
The TRβ binding site was characterized by gel shift mobility assays, site directed 
mutagenesis and in vivo and in vitro luciferase constructs transfection techniques. In 
addition, I have used the chromatin immunoprecipitation (ChIP) technique to confirm the 
binding of the TRβ to the PDK4 gene promoter. 
 
Transcription coregulators bind to nuclear receptors to facilitate or inhibit the 
transcription of the target genes. I have explored the role of several coregulators 
including the transcriptional coactivator peroxisome proliferator activated receptor 
gamma coactivator-1 (PGC-1α). Previous studies demonstrated that PGC-1α could 
induce the PDK4 gene.  Here, I found that T3 increases PGC-1α abundance and 
association with the PDK4 gene.  In addition, adenoviral shRNA-mediated knock-down 
of PGC-1α reduced the T3 induction of PDK4 and several other genes.  These data 
suggest that PGC-1α participates in the T3 induction of multiple genes in the liver. In 
addition, I investigated the role of several transcription factors including estrogen related 
receptor (ERRα), CCAAT/enhancer binding protein beta (C/EBPß) and the forkhead 
transcription factor (FOXO1) in the activation of the PDK4 gene by T3.  ERRα and 
FoxO1 recruit PGC-1α to the proximal PDK4 promoter and are involved in the 
synergistic stimulation of the PDK4 gene by T3 and PGC-1α. C/EBPß was identified as 
an important accessory factor in the T3 induction of the PDK4 gene.  Knock-down of 
C/EBPß with adenoviral shRNA decreased both the basal expression and T3 stimulation 
of PDK4.  Overall, my results showed that T3 induces PDK4 gene expression through a 
TRβ binding site in the promoter of the PDK4 gene and that the two transcription 
coregulators PGC-1α and C/EBPβ enhance this induction.  
 
Finally, I have tested the ability of T3 to induce a group of transcriptional 
regulators and metabolic genes. After 24 hours, 27 gens were found to be induced by T3 
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including several coactivators. These results suggest that T3 may induce a network of 
transcriptional regulators to further amplify the actions of T3.  
 
Thus, my studies have characterized the mechanism of the activation of an 
important metabolic gene, PDK4 gene, by T3 and identified the transcription factors that 
are involved in this mechanism. Also, my studies have provided a broad insight of the 
hepatic transcription factors network that work coordinately to facilitate the action of the 
T3 in the liver. This work may open a door to further investigate therapeutic targets in 
this network to modulate metabolic disease processes that are affected by the thyroid 
hormone.  
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CHAPTER 1: INTRODUCTION  
  
 
 This chapter provides an overview of the topics examined in this dissertation 
including thyroid hormone biology, the functions of the transcription coregulators and 
finally the role and the regulation of pyruvate dehydrogenase kinase 4.  
 
 
1.1 Thyroid hormone 
 
 
1.1.1 General biology 
 
Thyroid hormone plays an important role on various aspects of metabolism, 
development and differentiation of cells (Yen, 2001). The thyroid gland secretes the 
thyroid hormones, T4 and the more biologically active form T3. Most of the T4 
undergoes peripheral 5'-deiodination into the T3 form (Braverman et al., 1970; Kohrle, 
2000).  T3 increases the metabolic rate by stimulating almost every tissue in the body to 
produce mitochondrial proteins and by increasing the oxygen utilization in cells 
(Oppenheimer et al., 1987). Early studies showed that T3 treatment of hypothyroid rats 
triggers RNA synthesis in liver and alters the transcription of target genes (Miksicek & 
Towle, 1982; Tata et al., 1963; Tata & Widnell, 1966). T3 mediates its effect on gene 
expression through binding to the thyroid hormone receptors (TRs) (Munoz et al., 1988; 
Schueler et al., 1990). Thyroid hormone receptors belong to the superfamily of nuclear 
hormone receptors, which are a class of ligand activated proteins that, when bound to 
specific sequences of DNA serve as transcriptional regulators within the cell nucleus. 
This family of nuclear receptors controls the development and differentiation of skin, 
bone, behavioral centers in the brain as well as the continual regulation of reproductive 
tissues and metabolism (Alaynick, 2008; Chung & Cooney, 2003; Francis et al., 2003). 
Currently about 48 nuclear hormone receptors have been discovered in human and they 
have been categorized according to their sequence homology into 6 subfamilies (Laudet, 
1997; Zhang et al., 2004c).  
 
The specific sequence that TRs bind to in the DNA sequence are known as T3 
response elements (TREs). TRs can bind to these sequences with or without ligand to 
produce its positive or negative regulation on the target genes (Rastinejad et al., 1995; 
Samuels et al., 1988). A putative consensus hexamer half-site sequence of 
[(G/A)GGT(C/G)A] was characterized for the TREs, based on mutational and sequence 
comparison studies. There is considerable variation in the primary nucleotide sequence as 
well as the number, spacing, and orientation of the half-sites (Cheng, 2000; Williams & 
Brent, 1995).  The half-sites for the TREs can be arranged as palindromes (TREpal), direct 
repeats (DRs), and inverted palindromes (IPs) and the optimal spacing between these 
half-site arrangements are zero, four, and six nucleotides, respectively. The most common 
TRE contains a direct repeat separated by 4 nucleotides (DR4) (Glass, 1994; Williams & 
Brent, 1995).  
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1.1.2 Thyroid hormone receptors  
 
There are two major TR isoforms encoded on separate genes, designated as TRα 
and TRβ. The primary transcript for each gene can be alternatively spliced, generating 
four thyroid hormone-binding receptors, namely TRα1, TRα2, TRβ1, TRβ2 and TRβ3 
(Chassande, 2003; Williams, 2000). All the TR isoforms bind thyroid hormone and 
mediate gene regulation except for TRα2 which encodes an altered ligand binding domain 
of unknown function (Munroe & Lazar, 1991). The TR isoforms in human, rat and mouse 
are highly homologous with respect to their amino acid sequences (Lazar, 1993). The 
TRs have several conserved domains including an A/B domain in the amino terminus and 
a DNA binding domains containing two zinc fingers.  Importantly, the ligand binding 
domain (LBD) contains the activation function-2 (AF-2) peptide that interacts with 
coactivators. TRα1, TRα2, TRβ1 and TRβ3 are expressed in most of the rat, mouse, and 
human tissues although their tissue specific abundance differs greatly (Bradley et al., 
1992; Hodin et al., 1990). However, the TRβ2 is restricted to pituitary and particular brain 
regions of the rodent (Bradley et al., 1992; Hodin et al., 1990; Lechan et al., 1994; Wood 
et al., 1991) and has not yet been detected in the human. Although both TRα1 and TRβ1 
are expressed in most tissues, TRα1 is highly expressed in skeletal muscle and brown 
adipose tissue whereas the TRβ1 is the most abundant form of TR in liver, kidney and 
brain (Lazar, 1993). In heart, TRα1 is most predominant TR isoform and is responsible 
for mediating thyroid hormone action in myocardiocytes, while in liver TRβ1 mediates 
the action of the thyroid hormone (Dillmann & Gloss, 2002).  
 
TRs can bind to the TREs as a monomer, homodimer or heterodimer with the 
retinoid X receptor (RXR). This heterodimerization with RXR enables the TRs to bind to 
asymmetric TREs and direct repeats separated by four nucleotides.   In the great majority 
of genes, TR binds as a heterodimer with RXR (Glass, 1994; Ribeiro et al., 1994).  
 
Thyroid hormone plays an important role in the regulation of genes involved in 
metabolism and development. The development of transgenic and knockout mouse 
models for the different TRs isoforms have helped us in understanding the molecular 
mechanisms of T3 action in normal and disease states. For example, the role of the 
thyroid hormone in pituitary gland had been identified by knockout studies done on the 
TRβ2 isoform, and it showed that TRβ2 may be playing the predominant role in regulating 
the thyroid stimulating hormone (TSH) (Abel et al., 1999). In heart knockout studies for 
the TRα1 and TRβ had showed that T3 maintains baseline heart rate through the TRα1, 
whereas T3 stimulates heart rate through TRβ (Johansson et al., 1999). In addition, the 
role of T3 in lipid synthesis and degradation had been examined in mice expressing the 
mutant TRβ. These mice had elevated serum cholesterol levels compared with control 
animals in both hypothyroid and hyperthyroid states (Hayashi et al., 1996). Moreover, 
using a mouse model of resistance to thyroid hormone where a point mutation in the 
ligand-binding domain of TRβ abolished its ability to bind to T3, Koshi Hashimoto 
reported cross talk between the liver X receptor α (LXRα) and the TRβ to regulate the 
cholesterol uptake and metabolism in liver. (Hashimoto et al., 2006). On the other hand, 
TRß-/- mice showed lowered stimulation of the cholesterol 7-α hydroxylase gene 
(CYP7A) mRNA level by T3 but not in TRα1-/- mice. These results indicate that TRß not 
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the TRα is the mediator of T3 action on CYP7A gene, the rate limiting enzyme in the 
process of the degradation of the cholesterol into bile acids, and consequently it is one of 
the major regulators of cholesterol metabolism in vivo. However, T3-deficient TRß-/- mice 
showed an augmented CYP7A response after challenge with dietary cholesterol, and 
these animals did not develop hypercholesterolemia to the extent as did wild type 
controls. The latter results lend strong support to the concept that TRs may exert 
regulatory effects in vivo independent of T3 (Gullberg et al., 2000). 
 
 
1.1.3 Thyroid hormone effects on glucose and fatty acids metabolism 
 
Lipid and glucose metabolism are among the many physiological processes that 
are regulated by thyroid hormone. In fact, there is a strong link between thyroid hormone 
disorders and number of widespread metabolic diseases including diabetes (Crunkhorn & 
Patti, 2008; Johnson, 2006; Wu, 2007), obesity (Kozlowska & Rosolowska-Huszcz, 
2004; Naslund, 2000; Ribeiro, 2008) and cardiovascular disease (Gomberg-Maitland & 
Frishman, 1998; Klein & Ojamaa, 2001). Along with heart and muscle, the liver is one of 
the main organs affected by T3 (Weitzel, 2003).  
 
In liver, T3 increases the abundance of a number of genes potentially involved in 
hepatic triglyceride production, including spot 14 and fatty acid transporter protein as 
well as a range of genes involved in hepatic lipogenesis and low density lipoprotein 
receptor expression (Feng et al., 2000; Ness & Zhao, 1994). Paradoxically, T3 
simultaneously induces genes involved in lipolysis including lipoprotein lipase (Pykalisto 
et al., 1976; Wahrenberg et al., 1994).  
 
Regarding glucose metabolism, T3 stimulates almost all aspects of carbohydrate 
metabolism, including enhancement of insulin-dependent entry of glucose into cells and 
increased gluconeogenesis through elevating the transcription of key gluconeogenic 
enzymes, such as glucose-6-phosphatase (G6P) and phosphoenolpyruvate carboxykinase 
(PEPCK) (Fowden et al., 2001; Park et al., 1997). In addition, T3 promotes 
glycogenolysis to generate free glucose (Johnson, 2006). 
 
Previous studies had detected at least two different gene expression pattern 
mediated by T3. Whereas limited number of genes were rapidly induced by T3 within 6 
hours only of in vivo T3 treatment, the majority of T3 regulated genes needed 24-48 
hours to be induced by the T3 treatment (Weitzel et al., 2003a; Weitzel et al., 2001). This 
observation led to the assumption that T3 can mediate gene expression by several 
mechanisms. One direct mechanism for the T3 mediated gene regulation is through 
binding of T3 to its TRE site on targeted gene promoter. The other mechanism is through 
the induction of an intermediate factor such as, the peroxisome proliferator activated 
receptor gamma coactivator-1 or the nuclear respiratory factor or CCAAT/enhancer 
binding protein beta that can in turn promote the induction of the targeted gene (Park et 
al., 1997; Weitzel et al., 2001; Zhang et al., 2004b). 
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Although detailed investigations have been performed to identify the mechanism 
by which T3 regulated different metabolic genes including phosphoenolpyruvate 
carboxykinase (PEPCK), carnitine palmitoyltransferase 1a (CPT-1a), apolipoprotein B 
(ApoB) and uncoupling protein 3 (UCP3) (de Lange et al., 2007; Jackson-Hayes et al., 
2003; Mukhopadhyay et al., 2003; Park et al., 1999; Zhang et al., 2004b), the mechanism 
of the induction of the pyruvate dehydrogenase kinase 4 (PDK4) gene by T3 had not been 
identified (Sugden et al., 1996). Understanding the mechanism of activation of PDK4 by 
T3 is an important step to fully understand the metabolic effect of the T3 on fatty acid 
and glucose metabolism as PDK4 is a key regulator in the pyruvate metabolism, which in 
turn affects both glucose and fatty acid metabolism (Jeoung & Harris, 2008; Sugden & 
Holness, 2002).   
 
  
1.1.4 Mechanism of the regulation of genes by thyroid hormone 
 
The thyroid gland produces tetraiodothyronine (T4), triiodothyronine (T3), and 
3,3',5'-triiodothyronine (rT3), however, the T4 is quantitatively the major secretory 
product (Moreno et al., 2008). There are three types of deiodinases, and they are 
responsible for the peripheral 5'-deiodination of T4 and T3 (Bianco et al., 2002; Kuiper et 
al., 2005). The first type is deioidinase I (D1) which is found in peripheral tissues such as 
liver and kidney and is responsible for the conversion of the majority of T4 to T3 in the 
blood circulation, while deiodinase II (D2) is predominant in brain, pituitary, and brown 
adipose tissue and primarily converts T4 to T3 for intracellular use. The third type is 
deioidinase III (D3), which is responsible for the generation of reverse T3 (rT3), which is 
the inactive form of the hormone. D3 is found primarily in placenta, brain, and skin (Yen, 
2001). D1 and D3 are also involved in the further degradation of T3 or T4 to distinct 
diiodothyronines: 3, 5-diiodothyronine (T2); 3, 3'-diiodothyronine (3, 3'-T2); and 3', 5’-
diiodothyronine (3', 5'-T2). And finally these, in turn, can be transformed into 
monoiodothyronine (T1) and subsequently into thyronine (T0) (Moreno et al., 2008). 
 
T3 binds to the thyroid hormone receptor (TR) which in turn binds to the thyroid 
response element (TRE) to modulate the transcription of target genes. However, the 
unliganded TRs can still bind to the TRE in the promoter of the targeted gene and can 
repress basal transcription of positively T3 regulated genes (Baniahmad et al., 1992; 
Brent et al., 1989). This basal repression is due to the direct interaction of unliganded 
TRs with corepressor molecules that typically posses the histone deacetylase activity and 
can interfere with the assembly of a functional preinitiation complex at the promoter of 
the target gene (Baniahmad et al., 1993; Tong et al., 1995). Nuclear receptor corepressor 
(NCoR) and the silencing mediator for retinoic acid receptor and thyroid receptor 
(SMRT) are corepressors that interact with unligaded TR (Horlein et al., 1995; Lee et al., 
1995). The consensus LXXI/HIXXXI/L sequences within the NCoR and SMRT interact 
with the amino acid residues on helices 3, 5, and 6, which are part of the ligand pocket 
and hinge region of the TRs (Nagy et al., 1999; Perissi et al., 1999). These corepressors 
interacts with other repressors as Sin 3 and histone deacetylase 1 (HDAC1), which in turn 
promotes histone deactylation and results in basal transcription repression (Heinzel et al., 
1997; Nagy et al., 1997). 
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When the ligand T3 is bound to the TR, it triggers significant conformational 
changes (Bourguet et al., 2000), including the repositioning of the helix 12 containing the 
core of AF-2 in the TR LBD (Glass & Rosenfeld, 2000), that results in release of the 
corepressor complex and recruitment of a coactivator complex to enhance transcription of 
the target gene (Onate et al., 1995). Most of the characterized coactivators interact with 
the LBDs of the TRs, through helical LXXLL motifs present within these coactivators 
(Heery et al., 1997). Several coactivators for the thyroid hormone transcription induction 
have been identified including the CREB binding protein (CBP) and the p300 protein 
complex, steroid receptor coactivator-1 (SRC-1) and PGC-1α (Chakravarti et al., 1996; 
Kamei et al., 1996; Rosenfeld et al., 2006; Weiss et al., 1999; Wu et al., 2002; Zhang et 
al., 2004b). These coactivators such as the CREB/p300 complex in turn interact and 
recruit the PCAF (p300/CBP-associated factor) to TRE site of the target gene. The PCAF 
has a histone acetyltransferase activity (HAT) which promotes hisone acetylation and 
transcription activation (Ogryzko et al., 1998).  
 
Therefore, the TR can shift between the unligaded and liganded form with T3 
causing the association or dissociation of coactivators or corepressors of the transcription 
machinery for the target genes (Figure 1.1) (Yen, 2001; Yen et al., 2006). As I 
mentioned before T3 can increase cardiac function via the TRα while elevating hepatic 
metabolism via TRβ. Thus, developing therapeutic agents that can promote the induction 
of metabolic genes by activating specific isoform of the TR can be beneficial for treating 
metabolic diseases as hypercholesteremia or obesity without provoking T3 cardiac side 
effects. Preliminary studies in animals with TRß selective agonists have led to a lowering 
of the triglyceride and cholesterol levels in animal models with less cardiac side effects 
(Baxter et al., 2004; Grover et al., 2004; Perra et al., 2008; Trost et al., 2000). All these 
facts show that understanding of the mechanism by which T3 regulate metabolic genes 
can lead to the identification of more therapeutic targets within its network of regulated 
genes for curing of related metabolic diseases.  
 
 
1.2 Transcription factors and coactivators 
 
 
1.2.1 General biology 
 
Transcription factors and their coregulators coordinately regulate many biological 
programs at the transcriptional level (Handschin & Spiegelman, 2006; Schrem et al., 
2002). Transcription factors control gene expression by binding to specific sequences 
frequently in the promoter upstream of the DNA of target genes and thereby control the 
transcription of their genetic information from DNA to RNA (Karin, 1990; Latchman, 
1997). Transcription factors are composed of two essential functional regions: a DNA-
binding domain and a transactivation domain. The DNA-binding domain is composed of 
amino acids that recognize specific DNA bases, while the activator domain of 
transcription factors contain the amino acids responsible for interacting with the 
components of the transcriptional apparatus (RNA polymerase) and with other regulatory 
proteins (transcription coactivators) (Agalioti et al., 2000; Senger et al., 2000). 
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Figure 1.1: Schematic model for the action of T3 on the regulation of gene 
transcription in liver cells. 
Abbreviations: CBP, cAMP-response element-binding protein; HDAC, histone 
deacetylase; P/CAF, p300/CBP-associated factor; RXR, retinoid X receptor; TRβ, 
thyroid hormone receptor beta; TRE, thyroid hormone-response element. 
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 Transcription coregulators are those proteins that either activate or repress the 
transcription of specific genes by interacting and regulating the transcription factors 
(Glass & Rosenfeld, 2000). Transcription coactivators are the coregulators that activate 
gene transcription, while those that repress it are known as corepressors. Transcriptional 
coactivators or corepressors regulate the transcription by binding to other DNA-bound 
factors without directly contacting DNA themselves (McKenna et al., 1999; Xu, 2005). 
Two different mechanisms have been identified for transcription coregulators to regulate 
the transcription of genes. The first mechanism for transcription coregulators is to modify 
chromatin structure through covalent modification of histones by acetylation, 
phosphorylation or methylation (Glass & Rosenfeld, 2000; Nowak & Corces, 2004; 
Stewart et al., 2005). The second mechanism is to modify the conformation of chromatin 
by an ATP-dependent process through altering chromatin structure by changing the 
location or conformation of the nucleosome. These structural changes do not involve 
covalent modification, and can either activate or repress the transcription (Aoyagi et al., 
2005; Kingston & Narlikar, 1999). 
 
Based on the structure of its DNA-binding domain, transcription factors are 
typically categorized into four groups including: basic domains, zinc-coordinating 
domains, helix-turn-helix domains and beta-scaffold domains with minor grove contacts  
(Stegmaier et al., 2004). The thyroid hormone receptor (TR) belongs to a zinc finger type 
of transcription factors, while the CCAAT/enhancer binding protein beta (C/EBPβ) 
belongs to the transcription factors with basic domains (leucine zipper type). On the other 
hand, one common feature of nuclear receptor coactivators is that they contain one or 
more LXXLL binding motifs. Different examples of transcription coactivators are listed 
here, androgen receptor associated protein, cAMP response element-binding protein-
binding protein (CBP), coactivator-associated arginine methyltransferase 1 (CARM1), 
steroid receptor coactivator (SRC), p300/CBP associating factor (p/CAF), and 
proliferator activated receptor gamma coactivator 1 (PGC-1) (Cai et al., 2005; El 
Messaoudi et al., 2006; Xu et al., 1999).  
 
In this dissertation I am focusing on the effect of two transcription factors the TR 
and the C/EBPβ on the activation of the PDK4 gene and the role of one transcription 
coactivator, the PGC-1α. I have discussed the thyroid receptor biology and function in the 
first part of this chapter and I will give an overview on the PGC-1α and the C/EBPβ in 
the following part of the introduction.  
 
 
1.2.2 PGC-1α as a transcription coactivator 
 
Mitochondrial biogenesis, hepatic gluconeogenesis, and β-oxidation of fatty acids 
are among many metabolic processes that are regulated by the transcription coactivator 
proliferator activated receptor gamma coactivator-1 alpha (PGC-1α) (Puigserver & 
Spiegelman, 2003). PGC-1α belongs to a family of transcriptional coactivators that 
includes PGC-1β and PGC-1 related coactivator (PRC) (Finck & Kelly, 2006). PGC-1α 
and PGC-1β are expressed in brown adipose tissue (BAT), heart, skeletal muscle, brain, 
kidney and liver (Finck & Kelly, 2006), but there is less information about the expression 
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patterns of PRC (Andersson & Scarpulla, 2001).  Physiological conditions that demand 
increased mitochondrial energy production such as exercising, fasting and cold exposure 
highly induce the expression of PGC-1α in skeletal muscle, in the heart, liver and brown 
adipose tissue (Baar et al., 2002; Lehman et al., 2000; Puigserver et al., 1998; Rhee et al., 
2003; Terada et al., 2002). Interestingly, fasting but not cold exposure induces PGC-1β, 
indicating that there are unique regulatory mechanisms of regulation for each coactivator 
and each activator may be involved in different metabolic pathways (Lin et al., 2002; Lin 
et al., 2003). 
 
PGC-1 has been implicated in the activation of many transcription factors 
including a number of nuclear receptors such as the peroxisome proliferator-activated 
receptors (PPAR) both the α and the β/δ isoforms (Vega et al., 2000; Wang et al., 2003), 
retinoid receptors (Puigserver et al., 1998), glucocorticoid receptor (Knutti et al., 2000), 
estrogen receptor (Knutti et al., 2000; Puigserver et al., 1998), farnesyl X receptor (FXR) 
(Zhang et al., 2004a), pregnane X receptor (PXR) (Bhalla et al., 2004), hepatic nuclear 
factor-4 (HNF-4) (Rhee et al., 2003), liver X receptor (LXR) (Lin et al., 2005b), and the 
estrogen-related receptors (ERRs) (Huss et al., 2002; Schreiber et al., 2003). 
PGC-1α was originally discovered as a cold-inducible transcription coactivator of 
adaptive thermogenesis in brown adipose tissue (BAT) (Puigserver et al., 1998). PGC-1α 
promotes mitochondrial biogenesis both in BAT and skeletal muscles through regulating 
the nuclear respiratory factors (NRF-1 and NRF-2) (Leone et al., 2005; Wu et al., 1999). 
Recent evidence also implicates PGC-1α in the regulation of glucose metabolism in 
muscles as it activates expression of glucose transporter 4 (GLUT4) in cultured skeletal 
muscle cells by coactivating myocyte enhancer factor-2 (MEF-2c) (Michael et al., 2001). 
Moreover, PGC-1α regulated fatty acid oxidation and fuel selection in muscle by 
activating the expression of the gene encoding pyruvate dehydrogenase kinase 4 via its 
NR partner, ERRα (Wende et al., 2005). Finally in liver and heart, PGC-1α promotes 
different metabolic processes. First, PGC-1α activate expression of PPARα target genes 
involved in hepatic and cardiac fatty acid oxidation (Huss & Kelly, 2004; Leone et al., 
2005; Vega et al., 2000). Second, PGC-1α coactivates HNF-4α and FOXO1 to drive 
expression of genes involved in gluconeogenesis in liver (Puigserver et al., 2003). Third, 
PGC-1α activates mitochondrial biogenesis in cultured cardiac myocytes (Lehman et al., 
2000). 
PGC-1α knockout mice further emphasized its important role for appropriate 
adaptation to the metabolic and physiologic stressors. Leone et al showed that PGC-1α -/- 
mice were unable to maintain core body temperature following exposure to cold, 
consistent with an altered thermogenic response (Leone et al., 2005). Also, they develop 
hepatic steatosis after a short period of starvation due to a combination of reduced 
mitochondrial respiratory capacity and an increased expression of lipogenic genes (Leone 
et al., 2005). On the other hand, the Spiegelman group reported that PGC-1α -/- mice are 
paradoxically lean and resistant to diet-induced obesity and that they did not develop 
hepatic steatosis. They showed diminished expression of genes involved in mitochondrial 
fatty acid oxidation, the TCA cycle, and oxidative phosphorylation (Lin et al., 2004). The 
mechanistic basis for the dissimilarities between the 2 lines of PGC-1α -/- mice is unclear 
(Finck & Kelly, 2006). However, both of them reported that PGC-1α -/- mice are cold 
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intolerant and they have a marked vacuolar lesions in the central nervous system together 
with compromised the capacity of their hearts to perform basal and strenuous aerobic 
work. Moreover, M. Patti had supported the central role of the PGC-1 system in human 
body metabolism as she reported that decreased PGC-1α and PGC-1β expression in 
human may be responsible for decreased expression of NRF-dependent genes, 
contributing to the metabolic disturbances characteristic of insulin resistance in type 2 
diabetes mellitus patients (Patti et al., 2003). 
The expression and activity of PGC-1α are linked to a variety of upstream cellular 
signaling pathways. Glucocorticoids and cAMP increased PGC-1α gene transcription in 
liver (Bernal-Mizrachi et al., 2003; Puigserver et al., 1998). While in muscles, the AMP-
activated protein kinase (AMPK), calcineurin A and calcium/calmodulin–dependent 
protein kinase (CaMK) and p38 mitogen-activated protein kinase (p38 MAPK) have been 
shown to activate PGC-1α (Fan et al., 2004; Schaeffer et al., 2004; Zong et al., 2002). 
The upstream signaling events and downstream gene regulatory actions for the PGC-1α 
coactivator in different body tissues are illustrated in Figure 1.2 (Finck & Kelly, 2006; 
Lin et al., 2005a). 
 The most important aspect regarding the PGC-1 coactivator system related to this 
dissertation is the ability of PGC-1α to coactivate the thyroid receptor and to induce the 
PDK4 gene (Puigserver et al., 1998; Wende et al., 2005). In addition, previous studies 
had reported that T3 highly induced the hepatic PGC-1α mRNA expression (Weitzel et 
al., 2001). Moreover, previous studies from our lab had reported that overexpression of 
the PGC-1α enhanced the induction of carnitine palmitoyltransferase 1a (CPT-1a) by 
thyroid hormone. All this information had linked the T3 effect on metabolic processes 
with the PGC-1α, but the role of the PGC-1α in the induction of PDK4 by T3 had not 
been investigated. Therefore, this dissertation aimed to answer this question, is the PGC-
1α is important for the hepatic action of T3 on PDK4 gene and other metabolic genes? 
 
 
1.2.3 C/EBPβ as a transcription factor 
 
The CCAAT/enhancer binding protein beta (C/EBPβ) is a heat-stable DNA-
binding protein found in rat liver nuclei. It belongs to a distinct subfamily of transcription 
factors called C/EBPs with several members (C/EBPα, C/EBPβ, C/EBPγ, C/EBPδ, 
C/EBPε, and C/EBPζ). They are encoded by separate genes located on different 
chromosomes (Landschulz et al., 1988; Williams et al., 1991). The C/EBPs are 
characterized by their ability to regulate different metabolic genes through binding 
selectively to the CCAAT motif in the promoters of these genes (Schrem et al., 2004). 
This group of proteins shares the highly conserved two homologous domains, the C-
terminal basic DNA binding domain and the leucine zipper dimerization domain. In 
addition, they contain two other less homologous domains, the N-terminal activation 
domain and the attenuation domain (Arizmendi et al., 1999).  
 
The expression patterns for the C/EBP isoforms are quite different as the C/EBPα 
is expressed in liver, adipose, intestine, lung, adrenal gland, placenta, ovary and 
peripheral blood mononuclear cells (PBMCs), while both C/EBPβ and C/EBPδ are 
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  Figure 1.2: The upstream signaling even stream gene regulatory 
actions for the PGC-1α coactivator in different body tissues. 
ts and down
The schematic indicates the upstream signaling events and downstream gene 
regulatory cascade for the actions of the PGC-1α coactivator in different tissues. 
Interaction of PGC-1α with its cognate transcription factor targets is shown linked to 
specific organ systems, together the target genes regulated and the altered metabolic 
process due to this regulation.  
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expressed in liver, intestine, lung and adipose tissue.C/EBPβ is also detectable in kidney, 
heart, and spleen by Northern analysis in the mouse (Cao et al., 1991). On the other hand, 
C/EBPε is expressed only in myeloid and lymphoid lineages. Finally, C/EBPγ and 
C/EBPζ are expressed ubiquitously (Lekstrom-Himes & Xanthopoulos, 1998). 
 
It is noteworthy that C/EBPs can bind to the DNA as homodimers or as 
heterodimers with other transcription factors (Schrem et al., 2004). Previous studies had 
demonstrated the ability of the C/EBP family to form hetrodimers with members of the 
cAMP-responsive-element-binding protein/ activating transcription factor (CREB/ATF) 
family of transcription factors especially ATF-2 and C/ATF (Fawcett et al., 1999; 
Shuman et al., 1997; Vallejo et al., 1993). C/EBP-ATF heterodimers bind to selective 
DNA sequences that are uniquely different than that for the C/EBP and ATF 
homodimers, as the C/EBP-ATF heterodimers bind to a so-called C/EBP-ATF composite 
site in the promoter region of regulated genes. C/ATF-C/EBPβ heterodimers bind to a 
subclass of asymmetric cAMP response elements exemplified by those in the 
phosphoenolpyruvate carboxykinase and proenkephalin genes (Vallejo et al., 1993). 
 
C/EBPβ expression is highly induced by lipopolysaccharide (LPS), IL-6, IL-1, 
dexamethasone, and glucagon, suggesting a role in the mediation of the inflammatory 
response (Alam et al., 1992; An et al., 1996; Matsuno et al., 1996). In adipose tissue, 
C/EBPβ is involved in the transcription of fat-specific genes (Christy et al., 1989; Yeh et 
al., 1995) and participates in the differentiation of pre-adipocytes (Bezy et al., 2007; 
Hamm et al., 2001). In addition, C/EBPβ regulates carbohydrate and lipid metabolism 
through binding and activating  a variety of genes encoding key metabolic enzymes 
including, but not limited to, phosphoenolpyruvate carboxykinase (PEPCK) and tyrosine 
aminotransferase (Garlatti et al., 1993; Park et al., 1990; Park et al., 1999; Wang et al., 
1996), fatty acid synthesis enzyme acetyl-CoA carboxylase (Tae et al., 1994) and the 
albumin gene (Friedman et al., 1989).  
   
 Several hormones including insulin, glucocorticoids and thyroid hormone 
regulate the transcription of the C/EBPβ and through this regulation they further control 
the expression of gluconeogenic genes (Duong et al., 2002; Ghosh et al., 2001; 
Menendez-Hurtado et al., 1997; Park et al., 1999). However, the most relevant point 
regarding this dissertation is the effect of thyroid hormone on the expression of C/EBPβ 
that had been reported by Menendez-Hurtado (Menendez-Hurtado et al., 1997). He found 
that during development, congenital hypothyroidism caused a significant decrease in both 
C/EBPα and C/EBPβ gene expression at early stages of postnatal development in liver 
(Menendez-Hurtado et al., 1997). This effect was tissue-specific since thyroid hormone 
had no effect on both C/EBPs mRNA levels in brown fat. Upon injection of those 
hypothyroid animals with thyroid hormone, there was a slow recovery of hepatic C/EBPα 
and C/EBPβ mRNA levels. Also, hypothyroid neonates had shown diminished C/EBPα 
and C/EBPβ protein levels, and the kinetics of induction of these proteins by thyroid 
hormone was faster than the one observed for the corresponding transcripts suggesting a 
translational or post-translational regulation of these genes as the major component of 
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thyroid hormone action on these proteins (Menendez-Hurtado et al., 1997). Also, studies 
from our lab had linked C/EBPβ  with the induction of PEPCK by thyroid hormone (Park 
et al., 1999). These information led us to investigate the role of C/EBPβ in induction of 
another important metabolic gene, the PDK4, by thyroid hormone.  
 
 
1.3 Pyruvate dehydrogenase kinase 4 (PDK4)  
 
 
1.3.1 General biology 
  
The pyruvate dehydrogenase complex (PDC) catalyzes the irreversible oxidative 
decarboxylation of pyruvate into acetyl-CoA. This reaction links the utilization of 
glycogen, glucose, and lactate with the citric acid cycle as well as fatty acid oxidation and 
synthesis, since acteyl-CoA can be used for fatty acid and cholesterol synthesis in the 
liver and fatty acid synthesis in adipose tissue. Prolonged fasting or high fat diets 
inactivate the PDC in order to minimize loss of pyruvate carbon to conserve it for 
maintaining the blood glucose levels needed through gluconeogensis. Another important 
reason for inactivating the PDC is to promote the usage of fatty acids as their primary 
energy source in as many tissues as possible. This in turn conserves body protein because 
amino acids are not oxidized for energy and less amino acid carbon has to be used for 
glucose synthesis (Randle, 1986; Sugden et al., 2001b).  
 
 All these observations indicate that regulating PDC is an important step in fuel 
selection for energy production in animals during different nutritional and hormonal 
states. Thus, the regulation of PDC is critical in glucose and fatty acids metabolism. PDC 
is regulated by the reversible phosphorylation reaction. Pyruvate dehydrogenase kinase 
(PDK) inactivates PDC by phosphorylation and pyruvate dehydrogenase phosphatase 
(PDP) activates PDC by dephosphorylation. Figure 1.3 illustrates the role of the PDK 
and PDP genes in the overall regulation process of the PDC activity (Sugden & Holness, 
2003).   
 
 
1.3.2 The role of the PDK in the regulation of the PDC 
  
 The mammalian pyruvate dehydrogenase complex is composed of three 
components: Pyruvate dehydrogenase (E1), the dihydrolipoamide acetyltransferase 
subunits (E2) and the dihydrolipoamide dehydrogenase (E3). E2 forms the core of the 
complex, while E1 is the enzyme responsible for decarboxylation of pyruvate. E1 binds 
noncovalently to an E1-binding domain on E2 as heterotetrameric α2β2 structure. E3 is 
the enzyme responsible for oxidation of the reduced lipoyl groups of E2 and the 
subsequent production of NADH, and it binds to the complex by the E3-binding protein 
(E3BP), as twelve E3-binding proteins anchor 12 E3 homodimers to each pyruvate 
dehydrogenase complex. Thus, each pyruvate dehydrogenase complex is composed of 
216 subunits (60 E2, 60 E1α, 60 E1β, 12 E3BP, and 24 E3) that sum up to about 9.5 MD 
(Harris et al., 2002).  
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Figure 1.3: The role of the PDK and PDP in the regulation process of the PDC and 
the related metabolic processes.  
PDC catalyzes the irreversible oxidative decarboxylation of pyruvate into acetyl-CoA. 
The PDC is regulated by the reversible phosphorylation reaction. Pyruvate 
dehydrogenase kinase (PDK) inactivates PDC by phosphorylation and pyruvate 
dehydrogenase phosphatase (PDP) activates PDC by dephosphorylation. The regulation 
of the PDC links with the glucose and fatty acid metabolism. NADH, nicotinamide 
adenine dinucleotide hydride; FFA, free fatty acids; PDP, pyruvate dehydrogenase; 
PEPCK; phosphoenolpyruvate carboxykinase.   
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 Although PDC activity is directly inhibited by the acetyl-CoA and NADH, the 
two byproducts of fatty acid and pyruvate oxidation, covalent modification of the PDC at 
the serine residues appears to be more important for regulating the PDC activity (Harris 
et al., 2002). Two regulatory enzymes are involved in this covalent modification, the 
PDK which inactivates the PDC through phosphorylation and the PDP which activate the 
PDC through dephosphorylation. Four PDK isoenzymes (PDK1, PDK2, PDK3 and 
PDK4) and two PDP isoenzymes (PDP1 and PDP2) are expressed in mammals (Bowker-
Kinley et al., 1998; Huang et al., 1998). The phosphorylation and the dephosphorylation 
occur at three serine residues number 203, 264 and 271 on the α-subunit of the E1 
element of the PDC (Harris et al., 2002; Sugden & Holness, 2003).  
 
 
1.3.3 PDK gene expression  
  
PDK consists of two subunits, the catalytically active α-subunit and the regulatory 
β-subunit. Four isoenzymes of PDK have been identified in mammalian tissues (PDK1, 
PDK2, PDK3 and PDK4) (Bowker-Kinley et al., 1998; Kwon & Harris, 2004; Rowles et 
al., 1996). The primary structure of PDK was determined for the first time by isolating a 
cDNA encoding a 48-kDa form of PDK, later termed PDK from a rat heart cDNA library 
(Popov et al., 1993). Based on analysis of the deduced amino acid sequences and crystal 
structures studies, it had been suggested that PDK does not belong to the eukaryotic 
serine/threonine protein kinases but rather it resembles the prokaryotic histidine protein 
kinases. Therefore, it had been assigned to the ATPase/kinase superfamily (composed of 
bacterial histidine protein kinases, DNA gyrases, and molecular chaperone Hsp90) 
(Bowker-Kinley et al., 1998; Popov et al., 1993; Steussy et al., 2001).  
 
 There is 66-74% homology in the primary structures between the four PDK 
isoenzymes: PDK3 and PDK4 are the most distinct and PDK1 and PDK2 the most 
conserved (Popov et al., 1994). Each PDK isoform is extremely similar in sequence 
between species, and PDK1 and PDK2 are >95% identical between rat and human 
(Sugden & Holness, 2003). The PDK2, PDK3, and PDK4 share the same molecular 
weight which corresponds to a 45-kDa, while only PDK1 has molecular weight of 48 
KDa (Sugden & Holness, 2003). 
 
 The mammalian PDK isoenzymes exhibit tissue-specific expression patterns 
(Bowker-Kinley et al., 1998). PDK1 expression has been detected in heart (Sugden et al., 
2000b; Wu et al., 1998), the pancreatic islet (Sugden et al., 2001a) and skeletal muscle 
(Peters et al., 2001). PDK2 is expressed ubiquitously with particularly high expression in 
heart, liver, and kidney (Bowker-Kinley et al., 1998), while PDK3 is expressed in testis, 
kidney and brain (Huang et al., 1998). Finally, PDK4 is highly expressed in several 
tissues, including heart (Sugden et al., 2000b; Wu et al., 1998), skeletal muscle (Holness 
et al., 2002; Holness et al., 2000; Peters et al., 2001), liver (Holness et al., 2003; Sugden 
et al., 2002), kidney (Bowker-Kinley et al., 1998; Sugden et al., 2001b) and the 
pancreatic islet (Sugden et al., 2001a).  
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 PDK isoenzymes show different kinetic parameters for phosphorylation site 
specificity in the regulation of PDC activity.  As I mentioned before, the phosphorylation 
of α-subunit of the E1 element of the PDC, occurs at three specific serine residues, 
serine-264 (designated phosphorylation site 1), serine-271 (phosphorylation site 2) and 
serine-203 (phosphorylation site 3) (Harris et al., 2002; Holness & Sugden, 2003; Sugden 
& Holness, 2003). PDC can be inactivated by phosphorylation of each site alone, 
although phosphorylation of site 1 is most rapid and site 3 phosphorylation least rapid. 
All four PDKs exhibit higher activity towards site 1 of free E1 compared with sites 2 and 
3. PDK2 exhibits the highest activity and PDK3 the lowest activity towards site 1. Hence, 
PDK2 activity may account for much of the short-term inhibition of PDC observed on the 
transition from the fed to the fasted state through phosphorylation of site 1. PDK4 
exhibits a much higher activity towards site 2 compared with PDK1, PDK2 and PDK3 
(Korotchkina & Patel, 2001). All four PDKs can phosphorylate sites 1 and 2, but site 3 
can be phosphorylated only by PDK1, this was demonstrated using recombinant mutant 
proteins of the E1 element of the PDC with a single functional phosphorylation site 
(Kolobova et al., 2001; Korotchkina & Patel, 2001). 
 
 
1.3.4 The role of the PDK4 gene in metabolic processes 
  
PDK4 is expressed in heart, skeletal muscle, liver, kidney and in the pancreatic 
islets. PDK4 is involved in the regulation of different metabolic processes within these 
tissues. In heart for example, Harris et al reported marked increase in the abundance of 
the PDK4 mRNA and protein in the hearts of rats that had been starved or rendered 
diabetic with streptozotocin (Wu et al., 1998). Re-feeding of starved rats and insulin 
treatment of diabetic rats very effectively reversed the increase in PDK4 protein, mRNA 
levels and restored PDK enzyme activity to levels of chow-fed control rats. On the other 
hand, little or no change in the amounts of PDK1 and PDK2 protein and the abundance of 
their messages occurred in response to starvation and diabetes, indicating that control of 
the amount of PDK4 is important in long-term regulation of the activity of the pyruvate 
dehydrogenase complex in rat heart (Wu et al., 1998). Also, Mary Sugden reported that 
hyperthyroidism and high fat feeding induced the expression of the PDK4 in hearts of 
rats (Sugden et al., 2000b), while in liver high-fat feeding increased hepatic PDK2, but 
not PDK4, protein expression whereas hyperthyroidism increased both hepatic PDK2 and 
PDK4 protein expression (Holness et al., 2003). However, Huang et al reported that free 
fatty acids are effective inducers of PDK4 expression in 7800C1 hepatoma cells (Huang 
et al., 2002).  Finally, high fat diets also induced the mRNA levels of the PDK4 gene in 
skeletal muscle (Sparks et al., 2006). In addition, starvation induced the PDK4 gene 
expression on both the RNA and protein levels not only in heart but in different 
mammalian tissues including liver and kidney (Wu et al., 2000). All these facts suggest 
that PDK4 may be the most important means of regulation of PDC activity during 
starvation and in diet-induced obesity.  
 
Therefore, PDK4 is involved in the regulation of glucose synthesis and fatty acid 
oxidation as PDK4 upregulation during starvation may participate in directing available 
pyruvate toward oxaloacetate formation in liver and kidney or to the lactate output rather 
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than oxidation in case of skeltelatl muscle, with subsequent use for glucose synthesis for 
entry into the gluconeogenic pathway and glucose synthesis (Sparks et al., 2006; Sugden 
& Holness, 2002, 2003; Sugden et al., 2000a). Indeed, blood concentrations of glucose, 
lactate, pyruvate, and alanine are low in PDK4-knockout (PDK4–/–) mice in the starved 
state (Jeoung et al., 2006), consistent with an important role for PDK4 in maintaining 
glucose levels during starvation. In addition, a recent PDK4–/– mice model showed lower 
fasting blood glucose levels, a slightly improved glucose tolerance, and slightly greater 
insulin sensitivity compared with wild-type mice (Jeoung & Harris, 2008). In the same 
time, these PDK4–/– mice have elevated levels of nonesterified fatty acids, ketone bodies, 
and branched-chain amino acids, consistent with slower rates of fatty acid oxidation. 
 
Several transcription factors and coactivators have been implicated in the 
regulation of the PDK4 gene expression and its downstream metabolic processes. 
Activation of PPARα in vivo enhances hepatic and renal PDK4 protein expression in the 
fed state promoting fatty acid oxidation (Huang et al., 2002; Sugden et al., 2001c). 
Furthermore, the upregulation of hepatic and renal PDK4 protein expression normally 
evoked in response to prolonged starvation is attenuated in PPARα-deficient mice 
(Sugden et al., 2001b; Sugden et al., 2002). In contrast, skeletal muscle PDK4 gene 
expression is suppressed by treatment of insulin-resistant rats with PPAR agonists, 
promoting lipid entrapment in adipose tissue (Way et al., 2001). Interestingly, the 
transcriptional coactivator PGC-1α that is in the core of this dissertation coactivates 
PDK4 gene expression via the orphan nuclear receptor ERRα, exerting reciprocal 
inhibitory influences on glucose catabolism while increasing alternate mitochondrial 
oxidative pathways in skeletal muscle (Wende et al., 2005). In addition, recent studies 
have also shown that the forkhead transcription factor FOXO1 and the glucocorticoid 
receptor (GR), two additional potential PGC-1α partners, directly regulate PDK4 
expression through consensus binding sites in the PDK4 gene promoter (Furuyama et al., 
2003; Kwon et al., 2004).  
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CHAPTER 2: RESEARCH OBJECTIVES AND SPECIFIC AIMS  
 
 
2.1 Research objectives 
 
 
2.1.1 Characterize the regulation of PDK4 gene by thyroid hormone 
  
Thyroid hormone (T3) is a key regulator of several processes including 
development, differentiation and metabolic balance. Among its cellular metabolic effects 
is the stimulation of fatty acid oxidation which is accompanied by a reduction in glucose 
utilization. This particular effect can be explained, in part, by the ability of T3 to induce 
the hepatic pyruvate dehydrogenase kinase (PDK4) gene expression. PDK4 suppresses 
glucose oxidation by its inhibitory effect on the pyruvate dehydrogenase complex (PDC) 
leading to an increase in fatty acid oxidation. T3 mediates its effect on gene expression of 
other genes through binding to a thyroid hormone receptor which is a nuclear receptor 
bound to the thyroid hormone response elements (TRE), frequently found in the 
promoters of these target genes. Upon T3 binding to the thyroid hormone receptor, the 
receptor undergoes a conformational change and recruits transcriptional coregulators 
which facilitate the regulation of transcription by T3. Peroxisome proliferator-activated 
receptor gamma coactivator-1 (PGC-1) and the CCAAT/enhancer binding protein 
(C/EBP) are among these transcription coregulators. Previous studies in our lab have 
demonstrated that PGC-1α and C/EBPβ are coactivators for the T3 induction of CPT-1a 
and PEPCK, respectively. In addition, the forkhead transcription factor (FOXO1) and the 
estrogen related receptor α (ERRα) are involved in the transcription regulation of PDK4 
and other metabolic genes.  
 
The induction of PDK4 gene by T3 was already documented; however, the 
mechanism of this activation has not been investigated. Both, the TRE site in the 
promoter of the PDK4 gene, and the transcription coregulators or the accessory factors 
that are involved in this activation, have not been identified. Therefore, the first 
hypothesis is that T3 activates PDK4 gene expression directly through a TRE site or 
indirectly through the recruitment of transcription factors and accessory proteins or 
through both mechanisms. To address this hypothesis, I characterized the PDK4 gene 
promoter to locate a TRE site, and I also tested whether PGC-1α and C/EBPβ participate 
in the T3 induction of the PDK4 gene. Also, the role of accessory factors as the ERRα 
and the FOXO1 in this induction was examined.  
 
 
2.1.2 Study the network of the transcription factors involved in the early response 
of hepatic metabolic genes to thyroid hormone  
  
Thyroid hormone regulates the expression of key metabolic genes including 
phosphoenolpyruvate carboxykinase (PEPCK), carnitine palmitoyltransferase 1a (CPT-
1a), apolipoprotein B (ApoB) and uncoupling protein 3 (UCP3). However, the detailed 
regulation of these genes is not fully understood. Moreover, previous studies 
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demonstrated that T3 elevates the abundance of many transcription factors and 
coactivators associated with mitochondrial biogenesis and lipid metabolism, such as 
PGC-1α, ERRα and lipins.  Therefore, the second hypothesis is that T3 stimulates 
metabolism in part by increasing a network of transcription factors that induce metabolic 
genes which may not contain a TRE site within their promoters. To address this 
hypothesis, I have examined the effect of treating primary hepatocytes with T3 for 24 
hours on 90 transcription factors and metabolic genes using superarray® real time PCR 
technology.  
 
 
2.2 Specific aims   
 
 The following are the specific aims for this dissertation: 
 
• SPECIFIC AIM 1: To characterize regulation of PDK4 gene by thyroid 
hormone. 
• SPECIFIC AIM 2:  To determine if T3 elevates expression of transcription 
factors involved in the regulation of metabolic genes. 
 
 
  
18 
 
CHAPTER 3: RESULTS AND EXPERIMENTAL PROCEDURES 
 
 
3.1 Results 
 
 
3.1.1 Identifying thyroid response elements (TREs) sites within the rPDK4 gene 
promoter  
  
Transcription of the PDK4 gene in the liver is induced by T3 in hyperthyroid rats 
(Sugden et al., 1996). However, the position of the TRE within the rPDK4 gene had not 
been determined. Therefore, the initial experiments were designed to localize and 
confirm the region in the rPDK4 promoter required for inducing rPDK4 transcription by 
T3. To localize a TRE in the PDK4 gene, I cotransfected HepG2 cells with rPDK4-
luciferase reporter constructs and an expression vector for TRß. First, I tested serial 
deletions of the PDK4 promoter driving the luciferase reporter. Deletion of the 283 
nucleotides between -1256 to -973 of the rPDK4 promoter abolished T3 responsiveness 
from 5.1 ± 0.4 fold induction of the -1256/+78 rPDK4 luciferase vector to 0.8 ± 0.1 with 
the -973/+78 rPDK4 luciferase vector (Figure 3.1A). The results are expressed as the 
relative induction by T3 ± S.E. by comparing the T3 induction of vectors in the T3 
treated cells to the non-treated ones.  These data suggested that there was a TRE in this 
region of the PDK4 promoter. I identified two potential TREs sites within this region of 
the rPDK4 promoter. These TREs resemble the well established putative consensus 
hexamer half-site sequence [(G/A)GGT(C/G)A] arranged as a direct repeat separated by 
four nucleotides (DR4) which is the optimal binding site for TR/RXR.  The putative 
TREs are shown in Figure 3.1B together with a model of the rat PDK4 promoter 
identifying the binding sites for ERRα, FOXO1 and PGC-1α.  
  
 I used site-directed mutagenesis of the PDK4 promoter to determine if either of 
these potential TREs was important for the T3 induction.  I disrupted the TRE1 by 
changing the (GGT) in the second hexamer half site sequence into (AAC), and for the 
TRE2 I changed the (GG) in its second hexamer half site into (AA).  Primers used to 
establish these mutations are listed in the experimental procedures section. To determine 
the effect of these mutations on the T3 responsiveness, I transfected HepG2 cells with the 
TRE1 mutant -1256/+78, TRE2 mutant -1256/+78 or the wild type -1256/+78 and tested 
for T3 responsiveness by luciferase assays.  TRE1 mutation caused a very significant 
reduction in the T3 responsiveness (1.5 ± 0.2 fold, 60% less than the wild type 3.8 ± 0.4 
fold, p = 0.0019).  On the other hand, the TRE2 mutation did not alter the T3 
responsiveness (4.4 ± 1.4, p = 0.299) (Figure 3.1C). 
 
 To further confirm the role of TRE1 in the T3 induction of the rPDK4 gene 
promoter, we preformed an in vivo transfection into the livers of hyperthyroid rats 
(Figure 3.1D). This experiment was conducted in collaboration with Dr. Gene Ness lab 
in University of South Florida, and was performed by his graduate student Lindsey 
Boone. The -1256/+78 rPDK4 luciferase vector wild type and the TRE1 mutant were 
transfected by electroporation into different spots of the same rat liver. 
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Figure 3.1: Localization and identification of the T3 responsive regions within the 
rPDK4 promoter that enhance T3 responsiveness. 
A. HepG2 cells were transiently transfected with 2 µg of different rPDK4 luciferase 
reporters, 1 µg of RSV-TRβ, and 0.1 µg of TK-renilla. For hormone treatment, cells were 
incubated either in serum-free DMEM or DMEM containing 100 nM T3 for 24 h. All 
transfections were performed in duplicate and repeated three to six times. Luciferase and 
renilla assays were performed in the same tube. Luciferase activity was corrected for both 
protein content and renilla activity which served as a transfection control. Results are 
expressed as the relative induction by T3 ± S.E. by comparing the T3 induction of vectors 
in the treated cells to the non-treated ones. The significance is calculated in relative to the 
shortest construct of the rPDK4-luciferase (-578/+78) (** = p value 0.001 to 0.01, *** = 
p value <0.001). B. A model of the rat PDK4 promoter is shown that contains the sites 
for the binding of the ERRα, FOXO1 and PGC-1α, also the sequence of the region 
between -1256 to -973 for the rPDK4 promoter with underlined potential TREs. C. 
HepG2 cells were transiently transfected with 2 µg of various -1256/+78 rPDK4 
constructs, 1 µg of RSV-TRβ, and 0.1 µg of TK-renilla. For hormone treatment, cells 
were incubated either in serum-free DMEM or DMEM containing 100 nM T3 for 24 h. 
All transfections were performed in duplicate and repeated three to six times. Luciferase 
assays were performed as described above. Results are expressed as the relative induction 
by T3 ± S.E. by comparing the T3 induction of vectors in the treated cells to the non-
treated ones. The significance is calculated in relative to the wild type rPDK4 -1256/+78-
luciferase (** = p value 0.001 to 0.01). D. Hypothyroid rats were transfected in vivo by 
electroporation of liver as outlined in the experimental procedures section. The 
transfection included the -1256/+78 wild type rPDK4-luciferase or the TRE1 mut 
rPDK4- luciferase plasmids. TK-renilla was included as a control. The hypothyroid rats 
were exposed to T3 three days before electroporation, with an additional half dose 
injection prior to the day of electroporation. The values are the average of four 
hypothyroid untreated rats and four T3 treated rats. 
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 Four hypothyroid rats were treated with T3 for 3 days before electroporation; with 
an additional half dose injection the day prior to electroporation. Another hypothyroid 
four rats were left untreated. In rats with T3 treatment, the expression of the wild type -
1256/+78 rPDK4 luciferase promoter increased significantly by 3.1 ± 0.6 fold (p =  0.01) 
in comparison to the mutant one, while in non-treated rats the induction of the wild type 
form was not significantly different than that of the mutant form being only 1.4 ± 0.2 fold 
(Figure 3.1D). 
  
 Finally, gel shift mobility assays were conducted with the wild type and the 
mutants oligomers for the TRE1 site to test the ability of the TRβ to bind this element in 
vitro. The results indicated that the TRβ can bind as a heterodimer with RXR to the wild 
type of the TRE1 site. However, TRβ did not bind the mutated TRE (Figure 3.2). The 
sequence of the oligomers used in this gel shift assays are indicated at the bottom of the 
panel.  
 
 These data prove that we had discovered a TRE site localized within the -1112 to 
-1096 region of the rPDK4 gene promoter, and that disruption of this site by site directed 
mutagenesis reduced the ability of the T3 to induce the rPDK4 gene.  
 
 
3.1.2 Association of the TRβ, PGC-1α and C/EBPβ with the PDK4 gene promoter in 
vivo 
  
 Previous studies from our laboratory have implicated the involvement of both 
peroxisome proliferator activated receptor gamma coactivator-1 alpha (PGC-1α) and 
CCAAT/enhancer binding protein beta (C/EBPβ) in the activation of different metabolic 
genes including the CPT-1a and PEPCK (Park et al., 1999; Song et al., 2004; Zhang et 
al., 2004b). To determine whether TRβ, PGC-1α and C/EBPβ were associated with the 
PDK4 gene in vivo, we conducted ChIP assays (Figure 3.3). Rat primary hepatocytes 
were exposed to 100nM T3 for 24 h or left in serum-free media. We cross-linked the 
hepatocytes with 1% formaldehyde prior to conducting immunoprecipitations with the 
TRβ or PGC-1α or C/EBPβ antibodies. As a control, we used the immunoprecipitation 
with rabbit pre-immune serum. We created PCR primers sets for the proximal, the TRE 
region, and an upstream promoter region of the PDK4 gene, and they are listed in the 
experimental procedures section. The upstream region served as a negative control. The 
data from the ChIP assays indicated that prior to T3 treatment both TRβ and C/EBPβ are 
associated with the proximal and the promoter region of the PDK4 gene around the TRE 
site. However, they are not associated with the upstream region of the PDK4 gene and the 
addition of T3 to hepatocytes did not increase the association of TRβ and C/EBPβ with 
the proximal or the TRE region.  On the other hand, the ChIP data show that prior to T3 
treatment PGC-1α can associate to the proximal region of the PDK4 gene promoter, and 
to a little extent to the TRE region of the promoter. Following treatment of hepatocytes 
with T3, the association of PGC-1α with the proximal region of the PDK4 gene increased 
by 1.85 ± 0.2 fold but T3 did not increase its association with the TRE region of the 
promoter (Figure 3.3). The TRβ, C/EBPβ and PGC-1α were associated to different 
extents with both the proximal and the TRE regions of the PDK4 
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TRβ             -                        +                       -                        + 
RXR            -                        +                       -                        + 
              
  
                  
  
TRE1 Wild type TRE1 Mutant 
  
 
TRE1 WT top oligo 
 
             GGGCTAAGGGCACCTTGGGTAACAAA 
TRE1 Mut top oligo              GGGCTAAGGGCACCTTGAACAACAAA 
  
  
   
Figure 3.2: TRβ binding site in the rPDK4 promoter. 
A gel shift mobility assay was conducted as described in the experimental procedures 
section using the oligomers for the potential TRE1 site and its mutated version. The 
sequences for these oligomers are given below the gel shift with the mutated nucleotides 
shown in bold, and the sequence for the wild type TRE is underlined. 
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Figure 3.3: TRβ, C/EBPβ and PGC-1α are associated with the rPDK4 gene 
promoter in vivo. 
A. Chromatin immunoprecipitation assays (ChIP) were conducted on primary rat 
hepatocytes. Hepatocytes were treated with 100nM thyroid hormone (T3) for 24 hours 
and then crossed linked with 1% formaldehyde as described in materials and methods. 
Antibodies to A. TRβ, B. PGC-1α and C. C/EBPβ, or immunoglobin G (IgG) were used 
for immunoprecipitations. The amplified PCR products using primers for the proximal, 
The PDK4-TRE and upstream region of the rPDK4 gene were resolved on an agrose gel. 
D. The association of TRβ, C/EBPβ and PGC-1α with PDK4-TRE and proximal were 
quantified using quantity one software. These data are the average ± SE of four 
independent ChIP assays (** = p value 0.001 to 0.01).  
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gene promoter but none of them were detected at the upstream control region of the 
PDK4 promoter. The data indicate that T3 through TRβ, C/EBPβ and PGC-1α can 
regulate the PDK4 transcription. This regulation may involve a looping of the proximal 
region of the promoter with its distal region that contains the TRE site. 
 
 
3.1.3 Thyroid hormone treatment increases the mRNA of both the PDK4 and PGC-
1α genes in primary rat hepatocytes.   
  
I examined the effect of thyroid hormone (T3) on the abundance of both PGC-1α 
and PDK4 mRNA in primary rat hepatocytes. Primary rat hepatocytes were treated with 
T3 for 24 h and then RNA was isolated. The mRNA abundance was measured by real 
time PCR. Both the PGC-1α and the PDK4 mRNA abundance were significantly 
increased 2.6 ± 0.7 fold and 2.2 ± 0.3 fold after T3 treatment in rat hepatocytes, 
respectively (Figure 3.4A). These data indicate that T3 can increase PGC-1α mRNA 
abundance in the liver. However, previous studies from our laboratory showed that PGC-
1α mRNA abundance did not change in heart after T3 treatment suggesting that T3 
induces PGC-1α in a tissue-specific manner (Zhang et al., 2004b). Next, I tested whether 
PGC-1α and PDK4 protein abundance were increased in response to T3 administration in 
rat hepatocytes. Using Western analyses to assess PGC-1α levels, we found that the PGC-
1α and the PDK4 protein abundance were increased 2.2 ± 0.2 fold and 2 ± 0.2 fold in 
response to T3 treatment, respectively (Figure 3.4B). These experiments provide further 
confirmation that the PGC-1α is a T3-responsive gene and supports our hypothesis that 
PGC-1α is a coactivator in T3 action for the PDK4 gene.  
 
 
3.1.4 PGC-1α enhances the thyroid hormone induction of the PDK4 gene and the 
role of the forkhead transcription factor (FOXO1) and the estrogen related receptor 
α (ERRα) in this enhancement. 
  
In the next experiments I examined the ability of PGC-1α to enhance the T3 
induction of the PDK4 gene. I conducted co-transfections of pSV-PGC-1α with the wild 
type -1256/+78 rPDK4-luc or the forkhead transcription factor (FOXO1) mutant at 
position -347 or the estrogen related receptor α (ERRα) mutants at positions -338 and -
370 of the -1256/+78 rPDK4-luc. Transfections were conducted in HepG2 hepatoma 
cells. Primers used to establish the mutations in the -1256/+78 rPDK4-luc are listed in the 
experimental procedures section. Addition of 100nM of T3 for 24 hours stimulated the 
wild type version of -1256/+78 rPDK4-luc vector by 8.4 ± 2 fold. In these experiments, 
overexpression of PGC-1α induced it by 4.3 ± 0.7 fold. When T3 was added in the 
presence of PGC-1α, I obtained a synergistic effect with 23.2 ± 4 fold induction. Also,  
when treating the -338 ERRα mutant, -370 ERRα mutant and -347 FOXO1 mutant 
versions of the rPDK4 -1256/+78 with T3 all of them showed luciferase induction by 
similar levels  7 ± 1.2 fold,  6.1 ± 1.3 fold and 7.1 ± 0.7 fold, respectively. However, the 
overexpression of PGC-1α did not induce either of the ERRα mutants or induced the -347 
FOXO1 mutant by 3.1 ± 0.6 fold only, which is still lower than the wild type -1256/+78  
induction.  
28 
 
Figure 3.4: Thyroid hormone increases PDK4 and PGC-1α mRNA and protein 
abundance in primary hepatocytes.  
A. Primary rat hepatocytes were plated on collagen-coated plates for 16 h. T3 was added 
at a concentration of 100 nM to the hepatocytes for 24 h. RNA was harvested, and the 
abundance of PDK4 and PGC-1α mRNA was determined by real time PCR. The data are 
presented as the fold induction of mRNA abundance by T3 (average ± SE) from four 
independent hepatocytes preparations, and the control samples were assigned a relative 
value of 1. B. The expression of the PDK4 and PGC-1α proteins was monitored by 
Western blot analysis using specific antibodies (1: 1000, Santa Cruz). The data are 
presented as the fold induction of protein abundance by T3 (average ± SE) from three 
independent hepatocytes preparations, and the control samples were assigned a relative 
value of 1 (* = p value 0.01 to 0.05, ** = p value 0.001 to 0.01). 
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But astonishing, when T3 was added in the presence of PGC-1α, I still obtained a 
significant synergistic effect for all the mutants versions of the -1256/+78 as follows: 
15.5 ± 3.5 fold for the -338 ERRα mutant, 11.6 ± 2 fold for the -370 ERRα mutant and 
20.1 ± 4.4 fold for the -347 FOXO1 mutant (Figure 3.5). These data indicate that PGC-
1α stimulates PDK4 gene primarily through the -338 to -370 region of the rPDK4 
promoter but, more importantly, that PGC-1α can act as a coactivator for the T3 induction 
of the PDK4 gene either through binding to its elements in the -338 to -370 region or may 
be through interacting with the thyroid receptor itself. For this reason we still observed a 
significant synergistic effect with T3 addition even though I mutated both ERRα sites in 
the promoter and PGC-1α alone by itself could not induce the PDK4 promoter. 
Supporting this concept are the ChIP data showing association of PGC-1α with the 
rPDK4 TRE site Figure 3.3D. Moreover, previous studies had detected an interaction 
between the PGC-1α and both the TRβ and RXR in vitro and in vivo (Delerive et al., 
2002; Puigserver et al., 1998; Wu et al., 2002). To further confirm this possibility I used 
adenoviral delivery of shRNA specific for silencing the PGC-1α in primary hepatocytes 
to see the effect of reduction in the PGC-1α gene expression on the hepatic T3 induction 
of PDK4 gene as.   
 
 
3.1.5 Knocking down of the PGC-1α in rat primary hepatocytes affects the ability of 
thyroid hormone to induce different metabolic genes. 
   
To test the role of the PGC-1α in the T3 induction of hepatic metabolic gene 
expression, I infected rat primary hepatocytes with adenovirus encoding the shRNA to 
silence the PGC-1α (Ad-siPGC-1α) for 16 hours prior to treatment of cells with T3 for 
additional 24 hours. Adenovirus encoding control shRNA that does not silence any rat 
genes was used as a control (Ad-NC). Ad-siPGC-1α significantly knocked down the 
expression of PGC-1α by 70% compared to the Ad-NC in hepatocytes non-treated with 
T3 (0.3 ± 0.04 fold relative to Ad-NC infected hepatocytes non treated with T3). In 
addition, the induction of PGC-1α by T3 treatment was reduced in hepatocytes infected 
with Ad-siPGC-1α (0.6 ±0.04 fold relative to Ad-NC infected hepatocytes untreated with 
T3) in comparison to that infected with Ad-NC (6.2 ± 3 relative to Ad-NC infected 
hepatocytes untreated with T3) (Figure 3.6A). The knock down of the PGC-1α in 
primary hepatocytes was accompanied by inability of T3 to induced the expression of 
PDK4, CPT-1a, PEPCK and C/EBPβ, while T3 had increased all these genes in 
hepatocytes infected with Ad-NC by 3.3 ± 0.9 fold, 3.9 ± 1 fold, 3.12 ± 0.52 fold, 1.7 ± 
0.35 fold, respectively (Figure 3.6B-E). This impairment of the T3 induction for these 
metabolic genes after PGC-1α silencing indicates that PGC-1α is an important 
coactivator in the T3 induction process of these genes in primary hepatocytes. 
  
 I have shown in this first part of the results chapter of this dissertation the ability 
of thyroid hormone to induce the PDK4 gene through a TRE and that PGC-1α enhanced 
this induction. When PGC-1α was completely silenced, thyroid hormone lost its ability to 
activate the PDK4 gene indicating that PGC-1α is an important coactivator in this 
process.  
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Figure 3.5: PGC-1α enhances the T3 induction of rPDK4 gene.  
HepG2 hepatoma cells were transiently transfected with 2 µg of different rPDK4-Luc 
constructs, 1 µg of pSV-PGC-1α or pSV, 1.0 µg of RSV-TRβ, and 0.1 µg of TK-Renilla. 
T3 was added at a concentration of 100 nM for 24 h. All transfections were performed in 
duplicate and repeated three to six times. Luciferase and renilla assays were performed in 
the same tube. Luciferase activity was corrected for both protein content and renilla 
activity which served as a transfection control. Results are expressed as fold induction by 
PGC-1α or T3 compared to the untreated cells in each data set (* = p value 0.01 to 0.05, 
** = p value 0.001 to 0.01, *** = p value <0.001).  
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Figure 3.6: The effect of knocking down the PGC-1α on the induction gene 
expression of the PDK4, CPT-1a, PEPCK and C/EBPβ by T3.  
Rat primary hepatocytes were infected with adenoviral vectors expressing shRNA for 
PGC-1α (Ad-siPGC-1α), or expressing control-shRNA (Ad-NC). After 24 h, hepatocytes 
were treated with T3 at a concentration of 100nM for another 24 hours. RNA was 
isolated from the cells, and the mRNA abundance of the indicated genes was measured 
by real time PCR. 18S rRNA was used as the control. The infections were repeated three 
times on independent plates of cells.  A. fold induction of the PGC-1α gene expression in 
hepatocytes in comparison to hepatocytes infected with Ad-NC and non-tretaed with T3. 
B. PDK4, C. CPT-1a, D. PEPCK and E. C/EBPβ mRNAs abundance were also measured 
in the same time with measuring the PGC-1α gene expression. The data are expressed as 
the mean of the fold induction ± S.E. of mRNA abundance relative to cells non-treated 
with T3 (* = p value 0.01 to 0.05, ** = p value 0.001 to 0.01). 
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Figure 3.6: (continued). 
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Figure 3.6: (continued). 
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 To further investigate the mechanism of PDK4 induction by thyroid hormone, I 
tested the role of another coregulator, C/EBPβ, that was associated with the PDK4 gene 
promoter by ChIP technique in the induction of PDK4 by thyroid hormone (refer to 
Figure 3.3C).  
 
 
3.1.6 Overexpression of C/EBPβ induces the rPDK4 gene luciferase promoter. 
  
Previous studies from our laboratory had shown that C/EBPβ is implicated in the 
T3 induction of the PEPCK gene (Park et al., 1999). Therefore, in the following part of 
this dissertation I investigated the role of the C/EBPβ as a coregulator in the induction of 
the PDK4 gene by T3. In the first experiment, I tested the ability of the C/EBPβ to induce 
the PDK4 gene promoter in the absence of T3. I conducted co-transfections of different 
serial deletions constructs of the rPDK4 promoter driving a luciferase reporter and MSV-
C/EBPβ in HepG2 hepatoma cells and measured the level of induction for these 
luciferase constructs. Luciferase assays showed that deletion of the 210 nucleotides 
between -788 to -578 of the rPDK4 promoter significantly reduced C/EBPβ 
responsiveness from 7.6 ± 0.7 fold to 3.3 ± 0.5 fold (p= 0.001), and also the deletion of 
the 255 nucleotides between -325 to -70 of the rPDK4 promoter significantly reduced 
C/EBPβ responsiveness from 4.4 ± 0.8 fold to 1.00 ± 0.3 fold (p= 0.005) (Figure 3.7). 
These data indicate that C/EBPβ can induce PDK4 gene expression and that at least two 
sites in the PDK4 gene promoter between nucleotides -788 to -578 and -325 to -70 are 
essential for its action. These data are consistent with the ChIP data (Figure 3.3C) where 
C/EBPβ was associated with both the proximal and the TRE site of rPDK4 gene 
promoter.  
 
 
3.1.7 Thyroid hormone treatment increases the C/EBPβ protein abundance in 
primary hepatocytes.  
  
The next question investigated whether C/EBPβ was regulated by T3. I treated 
primary rat hepatocytes with 100nM T3 for 24 h and extracted proteins. Using Western 
analyses to assess C/EBPβ protein level, I found that the C/EBPβ protein abundance was 
significantly increased by 2.1 ± 0.4 fold in response to T3 treatment (Figure 3.8). This 
experiment demonstrated that C/EBPβ abundance is modulated by T3 and raised the 
possibility that it may be a coregulator in T3 action for the PDK4 gene. 
 
 
3.1.8 C/EBPβ enhances the thyroid hormone induction of rPDK4 gene.  
  
In the next experiment, I examined the ability of the C/EBPβ to enhance the T3 
induction of the PDK4 gene. I conducted co-transfections of the wild type -1256/+78 
rPDK4-luc and MSV-C/EBPβ in HepG2 hepatoma cells with and without T3 addition. 
Addition of 100nM of T3 for 24 hours stimulated the wild type version of -1256/+78 
rPDK4-luc vector by 5.3 ± 1.1 fold. In these experiments, overexpression of C/EBPβ 
induced the PDK4-luc vector 4.7 ± 1.3 fold.  
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Figure 3.7: Overexpression of C/EBPβ induces the rPDK4 promoter.  
HepG2 cells were transiently transfected with 2 µg of different rPDK4 constructs, 1 µg of 
MSV-C/EBPβ, and 0.1 µg of TK-renilla. All transfections were performed in duplicate 
and repeated three at least three times. Luciferase and renilla assays were performed in 
the same tube. Luciferase activity was corrected for both protein content and renilla 
activity which served as a transfection control. Results are expressed as the relative 
induction by T3 ± S.E by comparing the T3 induction of vectors in the treated cells to the 
non-treated ones. The significance is calculated in relative to the shortest version of the 
rPDK4-luciferase (-70/+78) (** = p value 0.001 to 0.01, *** = p value <0.001).  
                            
39 
 
         
                                    T3              -                        +  
           C/EBPβ 
                                                Actinβ 
                                 
0
1
2
3
2.1 ± 0.4
*
In
du
ct
io
n 
of
 C
/E
B
Pβ
 p
ro
te
in
 b
y 
T3
 
Figure 3.8: Thyroid hormone increases the C/EBPβ protein abundance in primary 
hepatocytes.  
 
The expression of the C/EBPβ proteins was monitored by Western blot analysis using 
specific antibodies (1: 1000, Santa Cruz). The data are presented as the fold induction of 
protein abundance by T3 (average ± SE) from three independent hepatocytes 
preparations, and the control samples were assigned a relative value of 1 (* = p value 
0.01 to 0.05). 
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 When T3 was added in the presence of C/EBPβ, I obtained a significant 
synergistic effect with a 16.9 ± 5 fold induction (Figure 3.9). These data indicate that 
C/EBPβ can activate the PDK4 gene promoter and can act synergistically with the T3 to 
amplify its effect on the PDK4 gene promoter.  
 
To further demonstrate and confirm the role of the C/EBPβ protein in the 
induction of PDK4 transcription, I tested a set of specific dominant negative vectors. 
Hep4-C/EBP is a dominant negative C/EBP vector, which has the C/EBP leucine zipper 
attached to an acidic amphipathic helix containing 4 heptads repeats (Krylov et al., 1995). 
The amphipathic helix interacts with the basic region of C/EBP proteins to form a strong 
non-DNA binding heterodimer and inhibits all C/EBP proteins including both alpha and 
beta isoforms (Krylov et al., 1995). For controls, I used the hep4-CREB which is a 
dominant negative CREB protein with a CREB leucine zipper and an amphipathic helix 
(Ahn et al., 1998) and the hep4-Fos which is a dominant negative Jun vector with the Fos 
leucine zipper and an amphipathic helix (Olive et al., 1997). To examine the effect of 
these dominant negative proteins on the basal induction of the PDK4 gene, the -1256/+78 
PDK4-luc vector was cotransfected with three dominant negative vectors into HepG2 
cells and after 48 hours from the transfection, proteins were extracted from the cells and 
tested for the luciferase level induction. The dominant negative C/EBP reduced the basal 
levels of the PDK4 gene significantly by 32% (p= 0.02), while the dominant negative 
FOS did not have any effect on the basal level of the PDK4 gene and the dominant 
negative CREB even significantly doubled its basal level (p= 0.0007) (Figure 3.10A). 
The reason for the induction of the PDK4 gene basal level by hep4-CREB is not known. 
 
 To confirm the role of the C/EBP proteins in the induction of the PDK4 gene by 
T3, I cotransfected the -1256/+78 PDK4-luc vector with three dominant negative vectors 
into HepG2 cells and treated them with 100nM T3. Proteins were extracted from the cells 
and tested for the luciferase activity. Cotransfection with hep4-C/EBP inhibited the 4.5 ± 
1.3 fold induction of T3. Both the dominant negative CREB and FOS did not affect at all 
the induction by T3 (Figure 3.10B).  
 
 These data indicate that C/EBPβ induces the expression of the PDK4 gene and 
enhances the T3 induction of this gene. Inhibition of the C/EBP isoforms by dominant 
negative vectors abolishes the ability of T3 to induce PDK4 gene. However, the dominant 
negative vectors cannot differentiate between the two isoforms of the C/EBP and 
therefore, to pinpoint which isoform this involved in the T3 induction of the PDK4 gene, 
I used adenoviral shRNA delivery to specifically inhibit the C/EBPβ isoform in the 
primary rat hepatocytes. 
 
 
3.1.9 Knocking down C/EBPβ reduces the ability of thyroid hormone to induce 
PDK4 gene expression in primary rat hepatocytes. 
  
 To test the role of the C/EBPβ in the T3 induction of PDK4 gene expression, I 
infected rat primary hepatocytes with adenovirus encoding the shRNA to silence 
specifically the C/EBPβ (Ad-siC/EBPβ).  
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Figure 3.9: C/EBPβ enhances the T3 induction of the rPDK4 gene.  
HepG2 hepatoma cells were transiently transfected with 2 µg of -1256/+78 rPDK4-Luc 
constructs, 1 µg of MSV-C/EBPβ or MSV, 1.0 µg of RSV-TRβ, and 0.1 µg of TK-
Renilla. T3 was added at a concentration of 100 nM for 24 h. All transfections were 
performed in duplicate and repeated three times. Luciferase assays were performed as 
described in Figure 3.8. Results are expressed as fold induction by PGC-1α or T3 versus 
the untreated cells in each data set (* = p value 0.01 to 0.05, ** = p value 0.001 to 0.01). 
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Figure 3.10: The effect of inhibiting the C/EBP, FOS and CREB on the induction of 
rPDK4 by T3.  
A. The effect of inhibiting the C/EBP, FOS and CREB on the basal expression of the -
1256/+78 rPDK4 luc. HepG2 hepatoma cells were transiently transfected with 2 µg of -
1256/+78 rPDK4-Luc constructs, 1 µg of PSV-40, hep4-C/EBP, hep4-FOS or hep4-
CREB, 1.0 µg of RSV-TRβ, and 0.1 µg of TK-Renilla. Fourty-eight hours after the 
transfection, cells were collected. All transfections were performed in duplicate and 
repeated three times. Luciferase and renilla assays were performed in the same tube. 
Luciferase activity was corrected for both protein content and renilla activity which 
served as a transfection control. Results are expressed as fold induction by PGC-1α or T3 
versus the untreated cells in each data set (* = p value 0.01 to 0.05, *** = p value 
<0.001). B. The effect of inhibiting the C/EBP, FOS and CREB on the induction of the -
1256/+78 rPDK4 luc by T3. HepG2 hepatoma cells were transiently transfected with 2 
µg of -1256/+78 rPDK4-Luc constructs, 1 µg of PSV-40, hep4-C/EBP, hep4-FOS or 
hep4-CREB, 1.0 µg of RSV-TRβ, and 0.1 µg of TK-Renilla. T3 was added at a 
concentration of 100 nM for 24 h. All transfections were performed in duplicate and 
repeated three times. Luciferase assays were performed as described above. Results are 
expressed as fold induction by PGC-1α or T3 versus the untreated cells in each data set (* 
= p value 0.01 to 0.05, ** = p value 0.001 to 0.01). 
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 Hepatocytes were transduced with the adenoviruses for 16 hours prior to 
treatment of cells with T3 for another 24 hours. Adenovirus encoding control shRNA that 
does not silence any rat genes was used as a control (Ad-control). I obtained these 
adenoviruses from Dr. Jacob E. Friedman from University of Colorado at Denver 
(Schroeder-Gloeckler et al., 2007). Ad-siC/EBPβ significantly knocked down the 
expression of C/EBPβ by 65% compared to the Ad-NC in hepatocytes untreated with T3 
(0.4 ± 0.02 fold relative to Ad-control infected hepatocytes untreated with T3). In 
addition, the induction of C/EBPβ by T3 was reduced in hepatocytes infected with Ad-
siC/EBPβ (0.4 ± 0.04 fold relative to Ad-control infected hepatocytes untreated with T3) 
in comparison to that infected with Ad-control (1.8 ± 0.3 relative to Ad-control infected 
hepatocytes untreated with T3) (Figure 3.11A). The knock down of the C/EBPβ in 
primary hepatocytes was accompanied by a significant reduction in the T3 induction of 
PDK4, as T3 induced PDK4 only by  1.55 ± 0.24 fold while T3 had increased PDK4 in 
hepatocytes infected with Ad-control by 2.3 ± 0.2 fold (Figure 3.11B). This reduction of 
the T3 induction for the PDK4 gene expression after C/EBPβ silencing indicates that 
C/EBPβ is an important coregulator in the T3 induction process of the PDK4 gene 
expression in primary hepatocytes. 
  
 From the previous experiments, I have confirmed the induction of PDK4 gene by 
T3 treatment. I also showed that both the PGC-1α and C/EBPβ are important coregulators 
for this induction. However, previous studies had shown that thyroid hormone induces a 
number of metabolic genes. This implies a large network of genes and transcription 
factors that are involved in the T3 cellular and genomic actions (Weitzel et al., 2001; Yen 
et al., 2006).  Therefore, I designed the next experiment to identify the early response 
network of transcription factors and metabolic genes that are regulated following 24 
hours of T3 treatment involved in the thyroid hormone metabolic action.  
 
 
3.1.10 Thyroid hormone treatment induces a network of transcription factors and 
different metabolic genes in primary rat hepatocytes.  
 
 Thyroid hormone regulates the expression of key metabolic genes including 
phosphoenolpyruvate carboxykinase (PEPCK), carnitine palmitoyltransferase 1a (CPT-
1a), apolipoprotein B (ApoB) and uncoupling protein 3 (UCP3) (Boss et al., 2000; 
Jackson-Hayes et al., 2003; Mukhopadhyay et al., 2003; Park et al., 1997; Yen et al., 
2006). Also, previous studies demonstrated that T3 elevates the abundance of many 
transcription factors and coactivators associated with mitochondrial biogenesis and lipid 
metabolism, such as PGC-1α and ERRα (Xie et al., 1999; Zhang et al., 2004b). These 
facts indicate that T3 may stimulate metabolism in part by increasing a network of 
transcription factors that induce different metabolic genes which may or may not contain 
a TRE site within their promoters. To address this possibility, I treated primary rat 
heptocytes with 100nM T3 for 24 hours, and then RNA was isolated from these 
hepatocytes and from non-treated ones. RNA was assessed on a superarray, containing 
90 real time PCR primers for genes of transcription factors and metabolic genes, 
according to the manufacturer procedures using the Roche Light cycler 480 machine. A 
complete list of these genes is provided in the experimental procedures section. 
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Figure 3.11: The effect of knocking down the C/EBPβ on the induction gene 
expression of the PDK4 gene by T3.  
Rat primary hepatocytes were infected with adenoviral vectors expressing shRNA for 
C/EBPβ (Ad-siC/EBPβ) or expressing control-shRNA (Ad-control). After 24 h, 
hepatocytes were treated with T3 at a concentration 100nM for another 24 hours. RNA 
was isolated from the cells, and the A. PDK4 and B. C/EBPβ mRNA abundance was 
measured by real time PCR. 18 S rRNA was used as the control. The infections were 
repeated four to seven times on independent plates of cells. The data are expressed as the 
mean of the fold induction ± S.E. of mRNA abundance relative to cells non-treated with 
T3. 
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 The results from four independent hepatocytes preparations showed up-regulation 
of 27 genes by more than 1.5 fold relative to non-treated cells (Figure 3.12). Thyroid 
treatment significantly induced genes involved in glucose homeostasis and 
gluconeogenesis such as, glucose-6-phosphatase (G6pase) by 1.7 ± 0.2 fold, 
phosphoenolpyruvate carboxykinase (PEPCK) by 3.7 ± 1.1 fold, solute carrier family 2 
(facilitated glucose transporter), member 4 (Slc2a4) by 3.2 ± 0.6 fold, cytochrome P450 
2E1 (Cyp2e1) by 2.2 ± 0.7 fold (Lieber, 1999). On the other hand, T3 treatment induced 
genes involved in fatty acid oxidation and metabolism such as, 3-ketoacyl-Coenzyme A 
thiolase alpha subunit (Hadha) by 2.5 ± 0.05 fold, fatty acid binding protein 3/small 
heterodimer partner (Fabp3/SHP) by 2.5 ± 0.8 fold, solute carrier family 25 
carnitine/acylcarnitine translocase member 20 (Slc25a20) by  2 ± 0.5 fold, fatty acid 
binding protein 1 (Fabp1) by 2.7 ± 1 fold, carnitine palmitoyltransferase 1a (CPT-1a) by 
2 ± 0.6 fold, and acetyl-Coenzyme A carboxylase beta (Acacb) by 2.6 ± 0.8 fold. 
Interestingly T3 significantly induced genes involved in fatty acid and lipid synthesis 
including, solute carrier family 27 fatty acid transporter member 5 (Slc27a5) by 1.9 ± 0.3 
fold, fatty acid synthase (FAS) by 2.3 ± 0.3 fold.  
 
 Also, T3 treatment induced number of transcription factors such as, GA binding 
protein transcription factor, beta subunit 1 (Gabpb1) by 1.9 ± 0.4 fold, peroxisome 
proliferative activated receptor, delta (Pparδ) by 3.1 ± 1 fold, estrogen related receptor 
gamma (EsRRγ) by 2.5 ± 0.9, CCAAT/enhancer binding protein beta (C/EBPβ) by 2 ± 
0.7, sterol regulatory element-binding transcription factor 1 (Srebf1) by 3.5 ± 0.6 (Zhang 
et al., 2003), Sirtuin 1 (Sirt-1) which deacetylates proteins that contribute to cellular 
regulation (Frye, 1999), and the homeobox protein NK-2 homolog (Nkx2.5) that binds 
and activates the promoter of thyroid specific genes such as thyroglobulin, 
thyroperoxidase, and thyrotropin receptor (Civitareale et al., 1989; Dentice et al., 2006; 
Francis-Lang et al., 1992), it was increased by 2.8 ± 0.7 fold. In addition, T3 treatment 
showed induction of number of transcription coactivators such as, peroxisome 
proliferative activated receptor gamma coactivator-1 alpha (PGC-1α) by 2.3 ± 0.9 fold, 
peroxisome proliferative activated receptor gamma coactivator-1 beta (PGC-1β) by 3 ± 
1.1 fold, also T3 induced both lipin gene isoforms, 1 and 2, by 2.1 ± 0.7 and 3.6 ± 1.6 
fold, respectively.  
  
 Finally T3 treatment induced number of miscellaneous proteins involved in 
different metabolic processes including, deiodinase, iodothyronine, type II (Dio2) which 
is responsible for the activation of thyroid hormone by converting the prohormone 
thyroxine (T4) by outer ring deiodination (ORD) to bioactive triiodothyronine (T3) 
(Yen, 2001), it was increased by 3.7 ± 1 fold, pyruvate dehydrogenase kinase isoform 4 
(PDK4) by 3 ± 0.7 fold and both isoforms of the uncoupling proteins, 2 and 3 (UCP2 
and UCP3), involved in thermogensis, insulin secretion and fatty acid transportation 
anions (Fisler & Warden, 2006), T3 induced UCP2 and UCP3 by 3.2 ± 1.5 fold and 3.5 
± 1.6, respectively. 
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Figure 3.12: Effect of T3 on transcription factor and metabolic gene abundance in 
primary rat hepatocytes. 
Primary rat hepatocytes were plated on collagen-coated plates for 16 h. T3 was added at a 
concentration of 100 nM to the hepatocytes for 24 h. RNA was harvested using RNA-
STAT 60 and treated with Turbo DNase I to remove contaminating genomic DNA and 
further purified using the Qiagen RNeasy kit. The extracted total RNA was converted 
into cDNA using superarray RT2 First Strand Kit. The abundance of the transcription 
factors and metabolic genes mRNA was determined by superarray® real time PCR (RT2 
Profiler™ PCR Array System, SABiosciences cat # CAPR-0529F). This superarray 
contains primers for 90 transcription factors/metabolic genes and 6 controls. The cDNA 
was assessed on the superarray according to the manufacturer protocol with a Roche light 
cycler 480. The data are presented as the fold induction of mRNA abundance by T3 
(average ± SE) from four independent hepatocytes preparations and the control samples 
were assigned a relative value of 1. Only the genes that were induced by T3 treatment by 
more than 1.5 fold relative to non-treated cells are represented in this figure (* = p value 
0.01 to 0.05, ** = p value 0.001 to 0.01, *** = p value <0.001). 
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3.2 Experimental procedures 
 
 
3.2.1 Transient transfection of luciferase vectors 
 
PDK4-luciferase constructs (PDK4-luc) were transiently transfected into HepG2 
cells by the calcium phosphate method as previously described (Zhang et al., 2004b). 
Transfections included 2 µg of PDK4-luciferase along with SV40-thyroid hormone 
receptor β (SV40-TRβ), PSV-PGC-1α and TK-Renilla. For experiments with C/EBPβ; 
MSV-C/EBPβ was included in the transfection. Dominant negative vectors for C/EBP 
(hep4-CEBP), CREB (hep4-CREB) and FOS (hep4-FOS) were also transfected. Cells 
were transfected in Dulbecco's modified Eagle's medium containing 5% calf serum, 5% 
fetal calf serum and incubated overnight at 37 °C. Following two washes with phosphate-
buffered saline, the medium was replaced by Dulbecco's modified Eagle's medium 
containing no serum. Cells were treated with 100 nM T3 for 24 h. After T3 treatment, 
cells were lysed in Passive Lysis Buffer (Promega). Both luciferase and Renilla activity 
were measured using Promega dual luciferase reporter kit (cat# E1980). Protein content 
in each lysate was determined by Pierce BCA Protein assay kit (cat# 23225). Luciferase 
activity was corrected for both protein content and Renilla activity to account for cell 
density and transfection efficiency, respectively.  
 
 
3.2.2 Site directed mutagenesis of the rPDK4 promoter  
  
Stratagene’s Quick-change-XL site directed mutagenesis kit was used to carry out 
mutation in the potential TREs in the -1256/+78 rPDK4-luciferase vector. TRE1 was 
disrupted by changing the (GGT) in its second hexamer half site sequence into (AAC), 
while the TRE2 was disrupted by changing only two nucleotides (GG) in its second 
hexamer half site into (AA). In addition, site directed mutagenesis technique was used to 
carry out mutations in the ERRα and FOXO1 binding sites in the -1256/+78 rPDK4-
luciferase vector. Mutations of the ERRα binding site are named Mut338 and Mut370, 
while the mutation of the FOXO1 binding site is named Mut347. Primers used to 
establish all these mutations are listed in Table 3.1, mutated nucleotides are in bold. 
 
 
3.2.3 In vivo luciferase transfection  
  
In vivo transfection of the wild type and mutated TRE1 -1256/+78 was done by 
electroporation in hypothyroid (by hypophysectomy) rats livers. Four hypothyroid rats 
were used without thyroid treatment and another 4 rats were treated with T3 three days 
prior to electroporation, with an additional half-dose injection the day before 
electroporation. This experiement was done in Dr. Gene Ness lab in University of South 
Florida. Electroporation was performed as previously described (Lagor et al., 2007). 
Approximately 16 µg of plasmid in 40 µl of sterile saline was subcaspsular injected using 
a 30-gauge, 3/8-in length needle and it was visible below the capsular surface as a 
blanched out area after injection. A circular six-node electrode was placed on the liver 
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Table 3.1: Sequences of the primers used for the site-directed mutagenesis of the 
rPDK4 promoter.  
TRE region Primer sequence
 
MutTRE1 
Forward 
 
5'-GAGGGCTAAGGGCACCTTGAACAACAAACTGCCTTTGCTGC-3' 
MutTRE1 
Reverse 
5'-CTCCCGATTCCCGTGGAACTTGTTGTTTGACGGAAACGACG-3' 
MutTRE2 
Forward 
5'-GAGTGAACAGAAGAGCGAGAGAAATTAGGATGAGAGTTTTATGAC-3' 
MutTRE2 
Reverse 
5'-CTCACTTGTCTTCTCGCTCTCTTTAATCCTACTCTCAAAATACTG-3' 
Mut338 
Forward 
5'-AGATGGCTCCTGAGTTGTAAACAAAAACAAGTCTGGGCGGG-3' 
Mut338 
Reverse 
5'-CCCGCCCAGACTTGTTTTTGTTTACAACTCAGGAGCCATCT-3' 
Mut347 
forward 
5'-TGACATTGAGATGGCTCCTGAGTTTGCAACAAGGACAAGTCTGGGC-3' 
Mut347 
Reverse 
5'-GCCCAGACTTGTCCTTGTTGCAAACTCAGGAGCCATCTCAATGTCA-3' 
Mut370 
forward 
5'-CAGTTTCTGGCGAGGAATGCGTGTTCGTGAGATGGCTCCTGAGTTGTAA-3' 
Mut370 
Reverse 
5'-TTACAACTCAGGAGCCATCTCACGAACACGCATTCCTCGCCAGAAACTG-3' 
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area where the plasmid was visible, so that each rat liver was electroportaed with both the 
wild type and the mutated version of the -1256/+78 plasmid, in different spots of the 
liver. Electrodes were sunk to a controlled depth of 2 mm using a rubber spacer. 6 x 150-
msec pulses at 100 V/cm, with a 150-msec rest between pulses were used to perform the 
transfection for optimal gene delivery to the liver with minimal tissue damage. To control 
for transfection efficiency, a plasmid-encoding renilla luciferase was cotransfected. After 
electroporation, the liver was placed back in the abdomen, and the wound was closed 
with surgical staples. At the time of surgery, animals were given a single subcutaneous 
injection of ketoprofen (5 mg/kg) for analgesia.  
 
 The results are expressed as the mean of luciferase activity of the wild type -
1256/+78 rPDK4-luciferase to that of the TRE1 mutated -1256/+78-luciferase for the 
hypothyroid rats or T3-treated rats. 
 
 
3.2.4 Electrophoretic mobility shift 
   
Electrophoretic mobility shift assays were conducted by labeling double-stranded 
oligonucleotides with Klenow enzyme and [α-32P]dCTP.  Oligonucleotides were designed 
that contain sequences for the TRE1.  The mutated oligomers for each site (See Figure 
3.2 for oligomer sequences) are identical to the mutations introduced into the PDK4-luc 
by site directed mutagenesis.  His-tagged TRβ and RXR proteins were used to determine 
the ability of binding the TRβ-RXR complex to bind to either the wild type or the 
muataed oligos (Bahouth et al., 1997; Park et al., 1997). The protein-DNA binding 
mixtures contained labeled probe (30,000 cpm) and the purified protein in 80 mM KCl, 
25 mM Tris-HCl (pH 7.4), 0.1 mM EDTA, 1 mM dithiothreitol, 10% glycerol and poly 
deoxyinosine-deoxycytidine; which is a nonspecific competitor. The binding reactions 
was incubated at room temperature for 20 min and then resolved on 5% non-denaturing 
acrylamide gels (80:1, acrylamide/bisacrylamide) in Tris-glycine running buffer (22 mM 
Tris and 190 mM glycine). The electrophoresis was carried out at 180 volts for 80 min at 
4 °C.  
 
 
3.2.5 Chromatin immunoprecipitation (ChIP) assay 
 
The ChIP assays were performed as follows. Rat primary hepatocytes were 
prepared extracted from rat liver tissues by collagenase perfusion as previously described 
(Deng et al., 2002). Rat primary hepatocytes (3 x 106 in 60-mm dishes) were maintained 
for 12 h in priming media of RPMI 1640 and 10% fetal bovine serum. Following two 
washes with phosphate-buffered saline, the medium was replaced by RPMI 1640 medium 
containing no serum. Then cells were treated with 100 nM T3 for 24 h. Cross-linking was 
performed with 1% formaldehyde for 15 min at room temperature and stopped by adding 
125 mM glycine to each plate for 5 min. Cross-linked hepatocytes were washed twice 
with ice-cold phosphate-buffered saline. Cells were scraped from the plate and collected 
by centrifuging for 5 min at 2,000 rpm. ChIP assays were conducted with slight 
modifications following the protocol given by the Millipore Magna 
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ChIP kit (#17-610). The cell pellets were resuspended in 200 µl of cell lysis buffer, 
containing protease inhibitor mixtures (P8340, Sigma). Samples were incubated on ice 
for 15 min and vortexed once, followed by homogenization using a Dounce homogenizer. 
The homogenate was pelleted, resuspended in nuclear lysis buffer, and 
sonicated to 400-600bp 9 x 30 seconds in ice water, followed by centrifugation at 14,000 
rpm for 10 min. Chromatin preparations were diluted with dilution buffer and protease 
inhibitor cocktail and designated as input samples (no antibody), used for 
immunoprecipitation with the desired antibody, or with the control antibody rabbit IgG 
(Santa Cruz # sc-2027). Antibodies used were anti-TRβ (sc-67122, Santa Cruz 
Biotechnology), anti-PGC-1α (sc-13067, Santa Cruz Biotechnology.), or anti-C/EBPβ 
(sc-150, Santa Cruz Biotechnology). Samples were left rotating overnight at 4º with the 
antibody and the A magnetic beads. The magnetic beads were pelleted and washed with a 
low-salt immune complex wash buffer, high-salt immune complex wash buffer, lithium-
chloride immune complex wash buffer, and TE buffer.  DNA was eluted using the ChIP 
elution buffer and treated with proteinase K for 4 hours at 65ºC followed by 10 
minutes at 95 ºC.  DNA was purified using the Qiaquick PCR purification kit  
(Qiagen, #28104). 
 
A total of 3–6 µl of purified sample was used in 35 cycles of PCR. Primers for 
regions of the target genes are listed in Table 3.2. The PCR products were analyzed on 
2% Nusieve 3:1 agarose (Cambrex, 50094) and visualized with MultiImage Light 
Cabinet with Alpha Imager EP software. The relative intensity of the bands was 
determined using AlphaView version 1.2.0.1 (Alpha Innotech Corporation).  
 
 
3.2.6 Real-time PCR 
  
For real time PCR, cDNA was prepared using RNA isolated from primary rat 
hepatocytes.  The RNA was isolated with RNA-Stat-60 (Tel-test) (Zhang et al., 2006).  
The RNA was then treated with DNase I (2 units) at 37 °C for 1 h followed by addition of 
DNase Inactivation Reagent (Ambion). The concentration of each sample containing 
DNA free RNA was measured using Nano drop machine (Thermo scientific).   Equal 
amounts of DNA-free RNA were used for first-strand cDNA synthesis. Two μg of   
DNA-free RNA extracted from different cells was converted to cDNA using Superscript 
reverse transcriptase III and random hexamers (Invitrogen).  The parameters for real time 
PCR were as follows: 95 °C for 10 min, 40 cycles of 95 °C 30 s and 60 °C 1 min. The 
final concentration of primers in each well in the PCR plates was 0.1 μM. . Four μl of 1:5 
of each cDNA was used as a template to assess target genes and the normalize control 
18S gene. The following forward (FP) and reverse primers (RP) were used for real time 
PCR to quanitate mRNA abundance: PDK4 forward primer, ggattactgaccgcctctttagtt; 
PDK4 reverse primer, gcattccgtgaattgtccatc; PGC-1α forward primer, 
atgaatgcagcggtcttagc; PGC-1α reverse primer, aacaatggcagggtttgttc; CPT-1a forward 
primer, cggttcaagaatggcatcatc; CPT-1a reverse primer, tcacacccaccaccacgat; 18S forward 
primer, cggctaccacatccaaggaa; 18S reverse primer, ttttcgtcactacctccccg. While the 
primers for both the C/EBPβ and the PEPCK were obtained from Qiagen (cat # 
QT00366478 and QT01619975, respectively).  
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Table 3.2: Sequences of the primers used in the ChIP assay to demonstrate 
interactions of TRβ, PGC-1α and C/EBPβ with the PDK4 gene. 
Regions of PDK4 gene 
amplified 
Forward primer (FP) Reverse primer (RP)
 
rPDK4, -591/-338 
(proximal) 
 
TAAGGCTATTTAGGCAGTTT 
 
CCAGACTTGTCCTTGTTTAC
 
rPDK4, -1535/-1228 
(TRE site) 
AGTGTCTCCACCAGATTGT CTAAGAGAGCTAACCTAGT
 
rPDK4, -6634/-6377 
(upstream) 
TATGAGAAGTGCTGCAATAA CCAGACTTGTCCTTGTTTAC
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 The results are relative quantification relates the PCR signal of the target 
transcript in treated cells to that of the untreated control cells using the delta delta CT 
method as described previously (Livak & Schmittgen, 2001). 
 
 
3.2.7 Western blot 
  
Western analysis was performed on whole cell extracts from non-treated primary 
rat hepatocytes or treated with 100nM of T3 for 24 hours.  Cells were lysed in RIPA 
buffer (20 mM Tris-Cl, pH 7.4, 150 mM NaCl, 0.5% deoxycholate, 5 mM EDTA pH 8.0, 
0.1% SDS, and diluted protease inhibitor mixture). The cells were vortexed for 1 minute. 
The cell membranes was removed by centrifugation for 25 min at 4 °C.  An equal amount 
of protein was loaded onto a 12% SDS-PAGE gel and transferred to a 0.45-µm pure 
nitrocellulose membrane (Bio-Rad). Blots were immunoblotted with primary antibodies 
(anti-PGC-1α, anti-C/EBPβ and anti-PDK4) in phosphate-buffered saline containing 5% 
nonfat dry milk powder and were incubated with horseradish peroxidase-conjugated anti-
rabbit secondary antibody. Immunoreactive proteins were identified using Super Signal 
West Femto Chemiluminescence Substrate (Pierce).  The ChemiDocTM XRS gel 
documentation system (Bio-Rad) was used to quantify the immunoreactive proteins.  
Actin was used as the loading control for each lane.  
 
 
3.2.8 Adenoviral infection 
  
Purified adenoviruses encoding shRNA specific for the PGC-1α (Ad-siPGC-1α) 
and control adenoviruses encoding non-template shRNA (Ad-NC) were amplified by 
Viraquest incorporation. The purified adenoviruses encoding shRNA designed for 
C/EBPβ targeting its 3'-untranslated region (5'-CCGGGCCCTGAGTAATCAC-3') were 
obtained from Dr. Jacob E. Friedman from University of Colorado, together with its 
control adenoviruses encoding non-template shRNA (Ad-control). Primary rat 
hepatocytes were plated at a density of 3 x 106 in a 60-mm dish in RPMI 1640 media (3 
plates for each condition).  Five hours after plating the cells, media was aspirated and 2 
ml of purified adenoviruses was added to the cells in the presence of 8ug/ml polybrene.  
The media was changed 24 hours post transduction and the cells were treated with 
100nM T3 for another 24 hours in serum free RPMI 1640.  The hepatocytes were 
harvested and RNA was isolated using RNA Stat 60 and converted to cDNA after DNase 
treatment and real-time PCR was performed according to the instructions stated under the 
real-time PCR section (see section 3.2.6). 
 
 
3.2.9 Superarray® real time PCR 
 
To investigate the role of T3 in the expression of different transcription factors, 
superarray® real time PCR (SABioscience) was performed. The superarray is a custom 
designed real time plate, containing primers for 90 transcription factors and 6 controls, 
complete list of the genes is provided in Table 3.3.  RNA was extracted from non-treated 
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rat primary hepatocytes and hepatoctes treated with T3 100nM for 24 hours as mentioned 
in section 3.2.6 Real-time PCR. The extracted RNA was converted to cDNA using first 
strand synthesis kit from SABioscience, the produced cDNA was then assessed on the 
superarray according to the manufacturer procedures using the Roche Light cycler 480 
machine. The parameters for real time PCR were as follows: 95 °C for 10 min, 40 cycles 
of 95 °C 15 s and 60 °C 1 min. 
  
57 
 
Table 3.3: Complete list of the genes primers on the superarray real time plate. 
Gene name Ref seq Gene symbol 
1. Acyl-CoA synthetase long-chain family 
member 1 NM_012820 Acsl 1 
2. Carnitine palmitoyltransferase 1a, liver NM_031559 Cpt1a 
3. Carnitine palmitoyltransferase 1b, muscle NM_013200 Cpt1b 
4. Carnitine palmitoyltransferase 1c XM_001075677 Cpt1c 
5. Carnitine acetyltransferase NM_001004085 Crat 
6. Solute carrier family 25 (mitochondrial 
carnitine/acylcarnitine translocase), member 
20 
NM_053965 Slc25a20 
7. Carnitine palmitoyltransferase 2 NM_012930 Cpt2 
8. Acyl-Coenzyme A dehydrogenase, very 
long chain NM_012891 Acadvl 
9. Acetyl-coenzyme A dehydrogenase, 
medium chain NM_016986 Acadm 
10. Cytochrome P450, family 2, subfamily e, 
polypeptide 1 NM_031543 Cyp2e1 
11. Malonyl-CoA decarboxylase NM_053477 Mlycd 
12. Acetyl-Coenzyme A carboxylase beta NM_053922 Acacb 
13. Hydroxyacyl-Coenzyme A 
dehydrogenase/3-ketoacyl-Coenzyme, alpha 
subunit 
NM_130826 Hadha 
14. Cd36 antigen NM_031561 Cd36 
15. Solute carrier family 27 (fatty acid 
transporter), member 1 NM_053580.2 Slc27a1 
16. Solute carrier family 27 (fatty acid 
transporter), member 2 NM_031736.1 Slc27a2 
17. Solute carrier family 27 (fatty acid 
transporter), member 4 XM_231115 Slc27a4 
18. Solute carrier family 27 (fatty acid 
transporter), member 5 NM_024143 Slc27a5 
19. Solute carrier family 2 (facilitated glucose 
transporter), member 2 NM_012879 Slc2a2 
20. Solute carrier family 2 (facilitated glucose 
transporter), member 4 NM_012751 Slc2a4 
21. Hexokinase 2 NM_012735 Hk2 
22. Phosphoenolpyruvate carboxykinase 1 NM_198780 Pck1 
23. Glucose-6-phosphatase, catalytic NM_013098 G6pc 
   
58 
 
Table 3.3: (continued).   
Gene name Ref seq Gene symbol 
24. Pyruvate dehydrogenase kinase, 
isoenzyme 2 NM_030872 Pdk2 
25. Pyruvate dehydrogenase kinase, 
isoenzyme 4 NM_053551 Pdk4 
26. Acetyl-coenzyme A acetyltransferase 1 NM_017075 Acat1 
27. 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 2 NM_173094 Hmgcs2 
28. 3-hydroxy-3-methylglutaryl-Coenzyme A 
lyase NM_024386 Hmgcl 
29. 3-hydroxybutyrate dehydrogenase, type 1 NM_053995 Bdh1 
30. 3-hydroxybutyrate dehydrogenase, type 2 
(predicted) XM_215705 Bdh2 
31. Stearoyl-Coenzyme A desaturase 1 NM_139192 Scd1 
32. Fatty acid desaturase 2 NM_031344 Fads2 
33. Acyl-Coenzyme A oxidase 1, palmitoyl NM_017340 Acox1 
34. Acyl-Coenzyme A oxidase 3, pristanoyl NM_053339 Acox3 
35. Hydroxysteroid (17-beta) dehydrogenase 4 NM_024392 Hsd17b4 
36. Acetyl-Coenzyme A acyltransferase 1 NM_012489 Acaa1 
37. Alpha-methylacyl-CoA racemase NM_012816 Amacr 
38. 2-4-dienoyl-Coenzyme A reductase 2, 
peroxisomal NM_171996 Decr2 
39. Acyl-CoA thioesterase 8 NM_130756 Acot8 
40. Phytanoyl-CoA hydroxylase NM_053674 Phyh 
41. ATP-binding cassette, sub-family D (ALD), 
member 1 (predicted) XM_343840 Abcd1 
42. Carnitine O-octanoyltransferase NM_031987 Crot 
43. ATP-binding cassette, sub-family D (ALD), 
member 2 NM_033352 Abcd2 
44. ATP-binding cassette, sub-family D (ALD), 
member 3 NM_012804 Abcd3 
45. Nuclear receptor subfamily 0, group B, 
member 2 NM_057133 Nr0b2 
46. Apolipoprotein A-IV NM_012737 Apoa4 
47. Peroxisomal biogenesis factor 11A NM_053487 Pex11a 
48. Acyl-CoA thioesterase 12 NM_130747 Acot12 
49. Fatty acid synthase NM_017332 Fasn 
50. Acetyl-coenzyme A carboxylase alpha NM_022193 Acaca 
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Table 3.3: (continued).   
Gene name Ref seq Gene symbol 
51. Protein phosphatase 2C, magnesium 
dependent, catalytic subunit NM_019372 Ppm2c 
52. Pyruvate dehydrogenase phosphatase 
isoenzyme 2 NM_145091 Pdp2 
53. Fatty acid binding protein 1, liver NM_012556 Fabp1 
54. Fatty acid binding protein 3 NM_024162 Fabp3/SHP 
55. Insulin receptor substrate 2 XM_573948 Irs2 
56. Thyroid hormone receptor alpha NM_001017960 Thra 
57. Thyroid hormone receptor beta NM_012672 Thrb 
58. Peroxisome proliferator activated receptor 
alpha NM_013196 Ppara 
59. Peroxisome proliferator activated receptor 
delta NM_013141 Ppard 
60. Peroxisome proliferator activated receptor 
gamma NM_013124 Pparg 
61. Estrogen related receptor, alpha NM_001008511 Esrra 
62. Estrogen-related receptor gamma NM_203336 Esrrg 
63. CCAAT/enhancer binding protein (C/EBP), 
alpha NM_012524 Cebpa 
64. CCAAT/enhancer binding protein (C/EBP), 
beta NM_024125 Cebpb 
65. CCAAT/enhancer binding protein (C/EBP), 
beta NM_024125 Cebpd 
66. Sirtuin 1 ((silent mating type information 
regulation 2, homolog) 1 XM_228146 Sirt1 
67. Peroxisome proliferative activated receptor, 
gamma, coactivator 1 alpha NM_031347 Ppargc1a 
68. Peroxisome proliferative activated receptor, 
gamma, coactivator 1 beta NM_176075 Ppargc1b 
69. Forkhead box O1A XM_342244 Foxo1a 
70. Forkhead box O3a (predicted) XM_215421 Foxo3a 
71. Forkhead box A2 NM_012743 HNF3b/FoxA2 
72. Lipin 1 NM_001012111 Lpin1 
73. Lipin 2 (predicted) XM_237521 Lpin2 
74. Sterol regulatory element binding factor 1 XM_213329 Srebf1 
75. Nuclear respiratory factor 1 (predicted) XM_231566 Nrf1 
76. GA repeat binding protein, beta 1 XM_344606 Gabpb1 
77. Similar to myocyte enhancer factor 2C NM_001014035 LOC309957 
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Table 3.3: (continued).   
Gene name Ref seq Gene symbol 
78. Nuclear receptor subfamily 2, group F, 
member 2 NM_080778 Nr2f2 
79. Uncoupling protein 2 (mitochondrial, proton 
carrier) NM_019354 Ucp2 
80. Uncoupling protein 3 (mitochondrial, proton 
carrier) NM_013167 Ucp3 
81. Diacylglycerol O-acyltransferase 1 NM_053437 Dgat1 
82. Diacylglycerol O-acyltransferase homolog 2 
(mouse) NM_001012345 Dgat2 
83. Superoxide dismutase 1 NM_017050 Sod1 
84. Superoxide dismutase 2, mitochondrial NM_017051 Sod2 
85. Cytochrome c oxidase subunit IV  
isoform 1 NM_017202 Cox4i1 
86. Citrate synthase NM_130755 Cs 
87. Deiodinase, iodothyronine, type II NM_031720 Dio2 
88. NK2 transcription factor related, locus 5 
(Drosophila) NM_053651 Nkx2-5 
89. Actin, beta NM_031144 ActB 
90. Ribosomal protein L13A NM_173340 RPL13A 
91. Glyceraldehyde-3-phosphate dehydrogenase NM_017008 GAPDH 
92. Genomic DNA Contamination control   
93. Reverse Transcriptase control   
94. Positive PCR control   
95. Positive PCR control   
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CHAPTER 4: DISCUSSION 
 
 Both thyroid hormone (T3) and the transcriptional coregulators (transcriptional 
factors & coactivators) play an important role in regulating the transcription of genes 
involved in the glucose and fatty acid metabolism. In this study, I focused on the role of 
the thyroid hormone receptor beta (TRβ), proliferator-activated receptor gamma 
coactivator-1 alpha (PGC-1α) and the CCAAT/enhancer binding protein beta (C/EBPβ) 
in the regulation of pyruvate dehydrogenase kinase 4 (PDK4) by thyroid hormone.  
 Pyruvate dehydrogenase kinases decrease the pyruvate dehydrogenase complex 
(PDC) activity by phosphorylation, thereby inhibiting the conversion of pyruvate to 
acetyl-CoA. Changes in PDC activity link glucose metabolism to fatty acid metabolism. 
PDKs facilitate gluconeogenesis by inhibiting PDC and preserving the three carbon 
compounds (pyruvate, lactate and alanine) as substrates for gluconeogenesis. At the same 
time, PDC inhibition (via PDKs) allows the oxidation of fatty acids to be the primary 
source of energy. Elevated gluconeogenesis and disturbance in fatty acid metabolism are 
observed in metabolic diseases as diabetes, obesity and hyperthyroidism (Basu et al., 
2005; Baxter et al., 2004; Chevalier et al., 2006; Crunkhorn & Patti, 2008; Kabir et al., 
2005; Wensaas et al., 2009). My studies that focused on the mechanism by which thyroid 
hormone regulates the transcription of the PDK4 gene and the role of the transcriptional 
coregulators in this regulation, have shed light on the role of thyroid hormone in both the 
glucose and fatty acid metabolism. In addition, I have provided a broad picture of the 
network of transcription factors and coactivators involved in the hepatic regulation of T3 
responsive metabolic genes.  
 
 
4.1 Regulation of the PDK4 gene expression 
 
 
4.1.1 The role of the thyroid hormone in the PDK4 gene expression 
  
T3 is a prominent regulator of the PDK4 gene expression and activity in heart, 
liver and skeletal muscles (Holness et al., 2003; Sugden et al., 2000a; Sugden et al., 
2000b). The transient transfection experiments done in this study showed that indeed T3 
can induce PDK4 gene expression in vitro in hepatoma HepG2 cells and in vivo in 
hyperthyroid rats. This stimulation was mediated through a TRE site found in the PDK4 
gene promoter designated as (agggcaccttgggtaa) which resembles the direct repeat 
separated by 4 nucleotides (DR4) type of TRE (Williams & Brent, 1995). We were the 
first to identify a TRE site within the rPDK4 promoter indicating that T3 can activate the 
PDK4 gene expression directly and not through an intermediate factor.  However, the 
identification of a TRE does not rule out a role of intermediate factors in the activation of 
the T3 induction. Therefore, I studied the role PGC-1α and C/EBPβ as two potential 
intermediate factors in this induction.  
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4.1.2 The role of the PGC-1α in the induction of the PDK4 by thyroid hormone 
  
Previous studies showed that there are links between the T3 metabolic actions and 
PGC-1α. First, PGC-1α coactivated the thyroid receptors (Puigserver et al., 1998; Wu et 
al., 2002). PGC-1α can also influence thyroid hormone action by altering RNA 
processing of TRα transcripts, thus modulating the ratio of TRα1 and TRα2 isoforms 
which is accompanied by a decrease in 5'-deiodinase expression (Thijssen-Timmer et al., 
2006). Second, Weitzel et al reported that the hepatic PGC-1α mRNA expression is 
induced by T3 treatment (Weitzel et al., 2001). Third, the enhancement of the induction 
of carnitine palmitoyltransferase 1a (CPT-1a) by thyroid hormone in the presence of 
PGC-1α was reported in previous studies (Zhang et al., 2004b). Finally, a recent review 
by Crunkhorn et al emphasized the potential linkage between PGC-1 coactivators and 
thyroid hormone action on the mitochondrial oxidation pathway (Crunkhorn & Patti, 
2008).  
 
In agreement with the proposed role of the PGC-1α in the T3 action, my 
experiments showed an association between the PGC-1α and both the proximal and the 
TRE site in the PDK4 promoter in vivo indicated by ChIP technique. Previous studies had 
reported that PGC-1α stimulated PDK4 (Wende et al., 2005). This association was 
increased significantly by thyroid hormone. Moreover, T3 treatment induced the mRNA 
and the protein level of both PDK4 and PGC-1α. In addition, overexpression of PGC-1α 
showed significant synergistic effect on the T3 induction of PDK4 gene expression. 
However, this synergistic effect was not abolished by mutating either the ERRα or the 
FOXO1 binding sites, indicating that PGC-1α is involved in the PDK4 regulation not 
only via the ERRα action but it can also exert its action through interacting with the TRs 
(Puigserver et al., 1998; Wu et al., 2002).  
 
Adenoviral-mediated silencing of the PGC-1α was utilized to investigate the role 
of the PGC-1α in the induction of PDK4 and other metabolic genes by T3. This 
experiment showed that silencing PGC-1α abolished the ability of T3 to induce PDK4, 
CPT-1a, PEPCK and C/EBPβ gene expression indicating that PGC-1α is an important 
coactivator for the T3 induction of these genes in primary hepatocytes. This experiment 
contrasts with a recent study conducted by Wetizel’s group, as they reported that 
silencing PGC-1α  had no effect on the induction of gene expression by T3 in rat pituitary 
(GC) cells (Wulf et al., 2007). In contrast with our studies, they measured the T3 effect 
on two other genes, glycerol-3-phosphate dehydrogenase (GPDH) and adenine nucleotide 
translocater 2 (ANT2). More importantly, they used GC pituitary cells, which are 
subclone of the rat GH3 pituitary tumor cell line and posses a different gene expression 
pattern than that of primary hepatocytes. The proliferation of GC cells are highly induced 
by T3 treatment (Barrera-Hernandez et al., 1999; Kitagawa et al., 1987; Laverriere et al., 
1986; Miller et al., 2001; Nass et al., 2000). On the other hand, T3 has no effect on the 
proliferation of hepatocytes in vitro (Kariv et al., 2003). All these data suggest that the T3 
regulation in pituitary GC cells is likely different than that for primary hepatocytes. It is 
also noteworthy that PGC-1α is underexpressed in immortalized tumor cell lines as it was 
reported in human hepatoma cells (Martinez-Jimenez et al., 2006). In addition, The role 
of PGC-1α in the T3 mediated gene expression in heart is still controversial. Two studies 
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had indicated that PGC-1 is potentially involved in mediating myocardial-specific 
remodeling of mitochondria in response to thyroid hormone treatment (Goldenthal et al., 
2004; McClure et al., 2005). However, two other studies had ruled out a role for the 
PGC-1α in the cardiac mitochondrial adaptations by T3 (Athea et al., 2007; Irrcher et al., 
2003), although, Irrcher et al stated that PGC-1α is still involved in the mitochondrial 
adaptation by T3 treatment in liver and skeletal muscles indicating that PGC-1α 
involvement in the T3 mediated gene expression is potentially tissue specific (Irrcher et 
al., 2003).  
 
On the other hand, number of previous studies support the results from the 
adenoviral-mediated silencing of PGC-1α experiment. One of these studies was 
conducted by the Spiegelman’s group as they reported that C/EBPβ was abnormally 
activated in the fed state in the PGC-1α null mice (Lin et al., 2004). Normally, fasting not 
feeding induced C/EBPβ in wild type mice (Lin et al., 2004). C/EBPδ was also induced 
in the fed liver lacking PGC-1α, while C/EBPα is expressed normally with respect to 
PGC-1α genotypes indicating that silencing PGC-1α alters expression of specific C/EBP 
isoforms. The aberrant induction of C/EBPβ and C/EBPδ, however, is absent when PGC-
1α-deficient hepatocytes are grown in cell culture, suggesting that systemic signals are 
likely responsible for their increased expression (Lin et al., 2004). Although, this study 
had linked the PGC-1α to the C/EBPβ gene induction by another physiological process 
which is feeding or fasting status and not T3 action, however, it supports our results that 
PGC-1α is an important regulator of C/EBPβ gene expression. Also, as supportive 
evidence Crunkhorn and Patti had stated in their review, that their unpublished data 
indicate that siRNA targeting PGC-1α or PGC-1β decreased the mRNA of TRα1 and 
mitochondrial genes in skeletal muscle (Crunkhorn & Patti, 2008). 
 
Based on the transient transfection, ChIP, and adenovirus mediating knockdown 
experiments done in this dissertation, we can model the mechanism by which PGC-1α 
coactivate the induction of PDK4 gene expression by T3 (Figure 4.1). In this model, T3 
increases the abundance of the PGC-1α so that more PGC-1α will be available to 
stimulate the PDK4 gene. PGC-1α can induce the PDK4 gene expression through the 
interaction with the ERRα at the proximal part of the PDK4 promoter (Wende et al., 
2005; Zhang et al., 2006). Also, PGC-1α can synergistically coactivate the T3 induction 
of the PDK4 gene by interacting with the TR and RXR at the TRE site of the PDK4 
promoter, even after disrupting the ERRα binding sites. 
 
 
4.1.3 The role of the C/EBPβ in the induction of the PDK4 by thyroid hormone 
 
Although, our lab and others had reported that C/EBPα is involved in the T3 
induction of number of genes (Jackson-Hayes et al., 2003; Jurado et al., 2002; Park et al., 
1997; Yin et al., 2005), to our knowledge only two studies had linked the C/EBPβ to T3 
action. The first study was done by Menendez-Hurtado, in which he reported that both 
C/EBPα and C/EBPβ gene expression decreased in liver of congenital hypothyroid rats 
during development (Menendez-Hurtado et al., 1997). Upon injection of those 
hypothyroid animals with thyroid hormone, there was an increase of hepatic C/EBPα and 
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Figure 4.1: PGC-1α is a coactivator in the T3 induction of the PDK4 gene 
expression. 
T3 activates the PDK4 gene expression directly through a TRE site and indirectly by 
stimulating the expression of the PGC-1α gene expression. Also, T3 increases the 
association between PGC-1α and the PDK4 promoter.  
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C/EBPβ mRNA and protein levels (Menendez-Hurtado et al., 1997). The second study 
was carried out by our lab, and we reported that C/EBPβ overexpression enhanced the T3 
induction of PEPCK (Park et al., 1999). 
 
In this study we are the first to report that overexpression of the C/EBPβ in 
transient transfections induced the PDK4 promoter. In addition, C/EBPβ enhanced the T3 
induction of PDK4 gene expression. Also, T3 treatment induced the C/EBPβ gene 
expression in primary hepatocytes. Moreover, adenoviral-mediated silencing of C/EBPβ 
experiments demonstrated that C/EBPβ is required for full induction of PDK4 mRNA by 
T3, as knocking down the C/EBPβ reduced the ability of T3 to induce PDK4 gene 
expression. The Ad-siC/EBPβ did not reduce significantly the basal levels of PDK4 
mRNA levels. These results are similar to studies done by the Friedman’s group, where 
they reported that C/EBPβ is not essential for maintenance of the basal PEPCK mRNA 
levels in C/EBPβ knockout mice (Arizmendi et al., 1999). However, C/EBPβ deletion 
limited the full induction of PEPCK and glucose 6-phosphatase genes in streptozotocin 
induced diabetic mice (Arizmendi et al., 1999). Although this study had linked C/EBPβ 
as essential factor for metabolic and gene regulatory responses to diabetes, it did not 
connect C/EBPβ to T3 action. However, C/EBPβ does modulate gluconeogenesis, a 
process regulated by both PDK4 gene and T3 (Fowden et al., 2001; Park et al., 1997; 
Sparks et al., 2006; Sugden & Holness, 2002). It is also noteworthy that C/EBPβ 
participates in the regulation of the PEPCK gene in response to different stimulus like 
cAMP, glucocorticoids and insulin (Croniger et al., 2001; Duong et al., 2002; Yamada et 
al., 1999). 
 
 
4.2 Transcription factors and metabolic genes involved in the thyroid hormone 
network in primary hepatocytes 
 
 Previous studies had showed that T3 regulates different aspects of both glucose 
and fatty acid metabolism. T3 simulates gluconeogenesis, cellular glucose uptake and 
glycogenolysis (Crunkhorn & Patti, 2008; Fowden et al., 2001; Johnson, 2006; Park et 
al., 1997). In addition, T3 stimulates triglyceride production, lipogenesis, lipolysis and 
fatty acid oxidation (Feng et al., 2000; Moreno et al., 2008; Ness & Zhao, 1994; Pykalisto 
et al., 1976; Ribeiro, 2008; Wahrenberg et al., 1994; Zhang et al., 2004b). 
 
 T3 exerts all these metabolic effects through inducing a network of transcription 
coregulators and metabolic genes (Weitzel et al., 2003a; Weitzel et al., 2003b; Weitzel et 
al., 2001). In this dissertation I used superarray® real time PCR arrays to identify 
selected metabolic genes and transcription coregulators that are regulated by 24 hours of 
T3 treatment in primary hepatocytes. Although, a similar experiment had been performed 
by the Weitzel’s group, this experiment was done using a broad microarray technique 
unlike my experimental approach which focused on transcription coregulators and 
metabolic genes involved in glucose and fatty acid metabolism (Weitzel et al., 2003a). 
Also, microarray sensitivity is different than real-time PCR sensitivity (Kubista et al., 
2006). Finally Wetizel’s experiment was done using RNA extracted from T3-treated 
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hypothyroid rats and outcomes from these rats can be different than that done using RNA 
extracted from cultured T3-treated primary hepatocytes from normal rats.  
 
 Indeed out of the 27 genes upregulated by T3 after 24 hours of treatment that I 
have reported in this study, only 4 genes, the two transcription coactivators PGC-1α and 
PGC-1β, Cytochrome P450 which is involved in both fatty acid oxidation and 
gluconeogenesis (Lieber, 1999), and fatty acid binding protein 1(Fabp1) involved in fatty 
acid metabolism (Kabir et al., 2005), are in common with that reported by Weitzel 
(Weitzel et al., 2003a). However, many of the genes detected in my study had been 
reported by previous studies to be stimulated by T3. In this study we reported the 
upregulation of some transcription factors like sterol regulatory element binding 
transcription factor (Srebf1), C/EBPβ, peroxisomal proliferator activated receptor delta 
(PPARδ). These factors had been reported to be induced by T3 treatment by other studies 
(de Lange et al., 2007; Menendez-Hurtado et al., 1997; Zhang et al., 2003). On the other 
hand, to our knowledge we are the first to report the T3 induction of transcription factors 
lipin gene isoforms 1 and 2, ERRγ, GA binding protein transcription factor, beta subunit 
1 (Gabpb1), Sirtuin 1 (Sirt-1) and transcription coactivator homeobox  protein NK-2 
(NKx2.5). It is important to mention in this aspect that lipin 1 was reported to be an 
amplifier of the PGC-1α /PPARα -mediated control of hepatic lipid metabolism and it 
exerts its action by direct interacting with both PGC-1α and PPARα (Finck et al., 2006). 
Also, Sirt-1 had been involved in the activation of PGC-1α by deacetylation (Gerhart-
Hines et al., 2007; Markus & Morris, 2008). Thus, upregulation of lipin 1 and Sirt-1 by 
T3 may be another way to regulate the activity of PGC-1α.  
  
Also, in this study we reported the T3 induction of genes involved in 
gluconeogenesis, PEPCK and G6pase and solute carrier family 2 (facilitated glucose 
transporter), member 4 (Slc2a4). All of them had been previously reported to be T3 
responsive genes (Fowden et al., 2001; Park et al., 1997; Torrance et al., 1997). For genes 
involved in fatty acid oxidation and synthesis, we are the first to report the T3 induction 
of 3-ketoacyl-Coenzyme A thiolase alpha subunit (Hadha), fatty acid binding protein 
3/small heterodimer partner (Fabp3/SHP), solute carrier family 25 carnitine/acylcarnitine 
translocase member 20 (Slc25a20), solute carrier family 27 fatty acid transporter member 
5 (Slc27a5) and acetyl-Coenzyme A carboxylase beta (Acacb). In addition, we reported 
the upregulation of carnitine palmitoyltransferase 1a (CPT-1a) and fatty acid synthase 
(FAS) by T3 treatment, which had been previously documented (Xiong et al., 1998; 
Zhang et al., 2004b).  
 
 Finally, using this superarray technique we reported the T3 induction of 
miscellaneous genes. First, deiodinase type II (Dio2) which is responsible for generation 
of T3 from T4 predominantly in brain, pituitary, and brown adipose tissue in mammals 
(Yen, 2001) and we detected its hepatic upregulation in response to T3 treatment. It was 
recently reported that Dio2 mRNA was detectable by real time PCR in livers of cows and 
in the livers of liver X receptors null mice (Capuco et al., 2008; Kalaany et al., 2005). 
Second, we confirmed PDK4 (gene of interest of this dissertation) upregulation by T3 
treatment. At last, uncoupling proteins 2 and 3 (UCP2 and UCP3) was also found to be 
T3 responsive genes. UCP3 was previously reported to be induced by T3 treatment (de 
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Lange et al., 2007), however to our knowledge we are the first to report upregulationn of 
UCP2 by T3 treatment.  
 
  Thus, this part of the dissertation has pinpointed the network of transcription 
coregulators and metabolic genes involved in T3 hepatic action. Further studies using 
knockout mice or mice injected using virus mediating silencing of these genes can 
indicate its importance in the T3 mediated hepatic gene expression.  
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APPENDIX: SUPPLEMENTAL DATA FOR CHAPTER 4 
 
 
 PGC-1α is involved in the activation of different metabolic genes by thyroid 
hormone. To further investigate the role of the PGC-1α in the T3 activation of other 
metabolic genes, we examined whether we could observe increased association of PGC-
1α to PDK4, CPT-1a and PEPCK in hypothyroid and hyperthyroid rats. Rats were made 
hypothyroid by the administration of propylthiouracil (PTU) and then they were treated 
with 100nM of T3 for 24 hours. Pieces of the liver were minced in 1% formaldehyde and 
then used in ChIP assays. Again we detected PGC-1α in the proximal region of the PDK4 
gene promoter, and this association was increased by 5.9 ± 0.5 fold after T3 treatment. 
However, we did not observe any association of PGC-1α with the TRE region of the 
PDK4 gene promoter. In addition, we observed increased association of the PGC-1α both 
the first intron and the TRE region of the CPT-1a gene promoter after T3 treatment by 
6.4 ± 0.8 fold and 2.2 ± 0.5 fold, respectively. Also, increased association of the PGC-1α 
with proximal region of the PEPCK gene promoter by 3.6 ± 0.8 fold was detected after 
T3 treatment (Figure A.1A and A.1B).  
 
 T3 not only increased the association of the PGC-1α with the above genes 
promoters, but it also increased the abundance of the PGC-1α protein itself in these 
hyperthyroid rats by 2.8 ± 0.3 fold (Figure A.1C). The increased abundance and 
association of the PGC-1α with different metabolic genes after T3 treatment suggests that 
T3 activation can work through the PGC-1α in the activation PDK4 and other metabolic 
genes.  
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Figure A.1: PGC-1α association with T3 responsive genes is elevated in 
hyperthyroid rats. 
A. ChIP assays were conducted in liver samples from hypothyroid rats that were 
untreated or exposed to T3 for 24 hours. The ChIP assays were conducted as outlined in 
the materials and methods. Various portions of the PDK4, CPT-1a and PEPCK genes 
were analyzed for the binding of PGC-1α. Representative PCR reactions are shown. B. 
The binding of PGC-1α to the various genes was quantified using quantity one software. 
The results are the summary of four independent hypothyroid and T3 rats. C. The 
abundance of PGC-1α was quantified using western blot analysis. The PGC-1α 
abundance was assessed using protein extracts from the same rats that were used for the 
ChIP assays. 
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Figure A.1: (continued).  
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